0001683168-23-007549.txt : 20231101 0001683168-23-007549.hdr.sgml : 20231101 20231101130938 ACCESSION NUMBER: 0001683168-23-007549 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231101 DATE AS OF CHANGE: 20231101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cavitation Technologies, Inc. CENTRAL INDEX KEY: 0001376793 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE SERVICES [0700] IRS NUMBER: 204907818 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53239 FILM NUMBER: 231367454 BUSINESS ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 BUSINESS PHONE: 818-718-0905 MAIL ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 FORMER COMPANY: FORMER CONFORMED NAME: Bioenergy Inc. DATE OF NAME CHANGE: 20060927 10-Q 1 cavitation_i10q-093023.htm FORM 10-Q FOR SEPT 2023
0001376793 false --06-30 2024 Q1 0001376793 2023-07-01 2023-09-30 0001376793 2023-10-31 0001376793 2023-09-30 0001376793 2023-06-30 0001376793 CVAT:RevenueFromCustomersMember 2023-07-01 2023-09-30 0001376793 CVAT:RevenueFromCustomersMember 2022-07-01 2022-09-30 0001376793 CVAT:RevenueFromJointVentureMember 2023-07-01 2023-09-30 0001376793 CVAT:RevenueFromJointVentureMember 2022-07-01 2022-09-30 0001376793 2022-07-01 2022-09-30 0001376793 us-gaap:CommonStockMember 2023-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001376793 us-gaap:RetainedEarningsMember 2023-06-30 0001376793 us-gaap:CommonStockMember 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2022-06-30 0001376793 2022-06-30 0001376793 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001376793 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001376793 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001376793 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001376793 us-gaap:CommonStockMember 2023-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001376793 us-gaap:RetainedEarningsMember 2023-09-30 0001376793 us-gaap:CommonStockMember 2022-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001376793 us-gaap:RetainedEarningsMember 2022-09-30 0001376793 2022-09-30 0001376793 CVAT:OneVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001376793 CVAT:TwoVendorsMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001376793 CVAT:OneVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0001376793 CVAT:TwoVendorsMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0001376793 CVAT:DesmetMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001376793 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001376793 us-gaap:StockOptionMember 2022-07-01 2023-06-30 0001376793 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001376793 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001376793 CVAT:DesmetMember CVAT:NanoReactorSalesMember 2022-07-01 2022-09-30 0001376793 CVAT:DesmetMember CVAT:NanoReactorSalesMember 2023-07-01 2023-09-30 0001376793 2021-10-01 2021-10-30 0001376793 CVAT:DesmetMember 2023-07-01 2023-09-30 0001376793 CVAT:AmeredevMember 2022-07-01 2022-09-30 0001376793 CVAT:AmeredevMember 2023-07-01 2023-09-30 0001376793 2023-01-01 2023-09-30 0001376793 CVAT:EIDLLoanMember 2020-07-01 2020-07-31 0001376793 CVAT:EIDLLoanMember 2020-07-31 0001376793 CVAT:EIDLLoanMember 2023-09-30 0001376793 CVAT:EIDLLoanMember 2022-09-30 0001376793 us-gaap:WarrantMember 2023-06-30 0001376793 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001376793 us-gaap:WarrantMember 2023-09-30 0001376793 CVAT:WarrantPrice1Member 2023-09-30 0001376793 CVAT:WarrantPrice1Member 2023-07-01 2023-09-30 0001376793 CVAT:WarrantPrice2Member 2023-09-30 0001376793 CVAT:WarrantPrice2Member 2023-07-01 2023-09-30 0001376793 CVAT:WarrantPrice3Member 2023-09-30 0001376793 CVAT:WarrantPrice3Member 2023-07-01 2023-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

  

FORM 10-Q

  

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

Commission File Number: 000-53239

 

 

Cavitation Technologies, Inc.
(Exact name of Registrant as Specified in its Charter)

 

Nevada 20-4907818
(State or Other Jurisdiction of Incorporation or Organization)  (I.R.S. Employer Identification Number)

 

10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA 91311
(Address, including Zip Code, of Principal Executive Offices)

 

(818) 718-0905
(Registrant's Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
     

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated Filer ☒ Small reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

 

As of October 31, 2023, the issuer had 284,289,740 shares of common stock outstanding.

 

   

 

 

TABLE OF CONTENTS

 

      Page
       
PART I.   FINANCIAL INFORMATION 3
       
Item 1.   Condensed Consolidated Financial Statements (unaudited) 3
       
    Condensed Consolidated Balance Sheets 3
       
    Condensed Consolidated Statements of Operations 4
       
    Condensed Consolidated Statement of Stockholders' Deficit 5
       
    Condensed Consolidated Statements of Cash Flows 6
       
    Notes to Condensed Consolidated Financial Statements 7
       
Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations 15
       
Item 3.   Quantitative and Qualitative Disclosures About Market Risk 18
       
Item 4.   Controls and Procedures 18
       
PART II   OTHER INFORMATION 19
       
Item 1.   Legal Proceedings 19
       
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds 19
       
Item 3.   Defaults Upon Senior Securities 19
       
Item 4.   Mine Safety Disclosure 19
       
Item 5.   Other Information 19
       
Item 6.   Exhibits 20
       
Signatures 21
   
Certifications  

 

 

 

 2 

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. Condensed Consolidated Financial Statements.

 

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

         
   September 30,   June 30, 
   2023   2023 
   (unaudited)     
ASSETS          
           
Current assets:          
Cash and cash equivalents  $140,000   $18,000 
Total current assets   140,000    18,000 
           
Property and equipment, net   1,000    1,000 
Equity method investment   1,000    1,000 
Operating lease right of use asset, net   95,000    113,000 
Other assets   10,000    10,000 
Total assets  $247,000   $143,000 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
Current liabilities:          
Accounts payable and accrued expenses  $144,000   $120,000 
Accrued payroll and payroll taxes due to officers   326,000    280,000 
Note payable   5,000    5,000 
Operating lease liability, current portion   68,000    68,000 
Advances from distributor   695,000    391,000 
Total current liabilities   1,238,000    864,000 
           
Note payable, non-current   145,000    145,000 
Operating lease liability, non-current portion   34,000    53,000 
Total liabilities   1,417,000    1,062,000 
           
Commitments and contingencies   –    – 
           
Stockholders' deficit:          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively   –    – 
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 284,289,740 shares issued and outstanding as of September 30, 2023 and June 30, 2023   284,000    284,000 
Additional paid-in capital   26,083,000    26,083,000 
Accumulated deficit   (27,537,000)   (27,286,000)
Total stockholders' deficit   (1,170,000)   (919,000)
Total liabilities and stockholders' deficit  $247,000   $143,000 

 

 

See accompanying notes to the condensed consolidated financial statements

 

 

 

 3 

 

 

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

AS OF SEPTEMBER 30, 2023 AND 2022

 

         
   For the Three Months Ended 
   September 30, 
   2023   2022 
   (unaudited)   (unaudited) 
         
Revenue  $–   $244,000 
Revenue from joint venture   –    17,000 
Total revenue   –    261,000 
           
Cost of revenue   –    (50,000)
Gross profit   –    211,000 
           
General and administrative expenses   214,000    265,000 
Research and development expenses   36,000    – 
Total operating expenses   250,000    265,000 
           
Loss from operations   (250,000)   (54,000)
           
Other expense:          
Loss from equity method investment   –    (18,000)
Interest expense   (1,000)   (1,000)
           
Net Loss  $(251,000)  $(73,000)
           
Net Loss per share, Basic and diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding, Basic and diluted   284,289,740    276,698,831 

 

 

See accompanying notes to the condensed consolidated financial statements

 

 

 

 4 

 

 

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)
AS OF SEPTEMBER 30, 2023 AND 2022

 

                     
   Three Months Ended September 30, 2023 (unaudited) 
   Common Stock  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Capital   Deficit   Total 
Balance at June 30, 2023   284,289,740   $284,000   $26,083,000   $(27,286,000)  $(919,000)
Net loss   –    –    –    (251,000)   (251,000)
Balance at September 30, 2023   284,289,740   $284,000   $26,083,000   $(27,537,000)  $(1,170,000)

 

 

   Three Months Ended September 30, 2022 (unaudited) 
   Common Stock  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Capital   Deficit   Total 
Balance at June 30, 2022   276,698,831   $277,000   $26,005,000   $(25,246,000)  $1,036,000 
Net loss   –    –    –    (73,000)   (73,000)
Balance at September 30, 2022   272,701,844   $272,000   $25,810,000   $(25,319,000)  $963,000 

 

 

See accompanying notes to the condensed consolidated financial statements

 

 

 

 5 

 

 

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

 

         
   Three Months Ended September 30, 
   2023   2022 
         
Net loss  $(251,000)  $(73,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Gain on forgiveness of note payable   –    18,000 
Effect of changes in:          
Accounts receivable   –    (17,000)
Operating lease right of use asset   18,000    17,000 
Accounts payable and accrued expenses   24,000    4,000 
Accrued payroll and payroll taxes due to officers   46,000    – 
Advances from distributor   304,000    (44,000)
Operating lease liability   (19,000)   (17,000)
Prepaid expenses   –    38,000 
Net cash provided by (used in) operating activities   122,000    (74,000)
           
Net increase (decrease) in cash and cash equivalents   122,000    (74,000)
           
Cash and cash equivalents, beginning of period   18,000    441,000 
Cash and cash equivalents, end of period  $140,000   $367,000 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $2,000   $– 
Cash paid for income taxes  $–   $– 

 

 

See accompanying notes to the condensed consolidated financial statements

 

 

 

 6 

 

 

CAVITATION TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Three months ended September 30, 2023 and 2022

 

Note 1 - Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America (“U.S.”) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2023 are not indicative of the results that may be expected for the fiscal year ending June 30, 2024. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2023 filed on October 3, 2023. The condensed consolidated balance sheet as of June 30, 2023 has been derived from the audited financial statements included in the Form 10-K for that year.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $251,000 and had a stockholders’ deficit of $1,170,000 as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2023, the Company has cash in the amount of $140,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

 

 

 7 

 

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of September 30, 2023 and June 30, 2023, the carrying value of its equity method investments was $1,000 for both periods presented.

 

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

 

 

 8 

 

 

There were no adjustments to net (loss) required for purposes of computing diluted earnings per share. At September 30, 2023 and September 30, 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive.

        
   September 30, 2023   June 30, 2023 
Options   –    1,250,000 
Warrants   53,657,234    53,657,234 

 

Concentrations

 

Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.

 

Accounts Payable and Accrued Expenses – two vendors accounted for 22% and 30% of accounts payable and accrued expenses as of September 30, 2023, respectively. Two vendors accounted for 52% and 36% of accounts payable and accrued expenses as of June 30, 2023.

 

Revenues – during the three-month period ended September 30, 2022, 93% of revenues were from Desmet.

 

Fair Value Measurement

 

FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

  · Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
     
  · Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
     
  · Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2023 and June 30, 2023, the fair values of cash and cash equivalents, accounts payable and accrued expenses, and accrued payroll and payroll taxes approximate their carrying values due to their short-term nature.

 

 

 

 9 

 

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

 

Note 2 - Contracts with Desmet Ballestra Group

 

October 2021, the Company executed a three-year agreement with Desmet Ballestra (Desmet), a company located in Europe. This agreement is a continuation of the October 2018 agreement that expired also in October 2021. In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet.

 

During the three months ended September 30, 2022, the Company recorded sales of $244,000 from Nano Reactor® sales from Desmet.

 

During the three months ended September 30, 2023 there were no sales from Nano Reactor to Desmet.

 

As part of the October 2021 agreement with Desmet, the Company also receives cash advances of $40,000 per month, subject to certain limitations, as advance payment for the sale of reactors. The Company initially records the advances received as “advances from distributor” a liability account, until such time revenue recognition is met. As of June 30, 2023, outstanding balance of customer advances amounted to $391,000.

 

During the three months ended September 30, 2023, advances received from Desmet amounted to $304,000.

 

As of September 30, 2023, outstanding advances from Desmet amounted to $695,000.

 

Note 3 - Investment in equity method investment

 

In April 2019, the Company and an unrelated entity, Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method in accordance with ASC 323 as the Company’s investments in Enviro, an unconsolidated entity and for which it has the ability to exercise significant influence but not control. From inception up to June 30, 2023, Enviro had no operations.

 

In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.

 

 

 

 10 

 

 

As of September 30, 2023 and June 30, 2023, the balance of the equity method investment amounted to $1,000, for both periods presented.

 

During the three months ended September 30, 2022, the Company recognized a loss of $17,000 related to the equity method investment. There was no similar transaction during the period ended September 30, 2023

 

Note 4 – Operating Lease

 

The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.

 

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

        
   September 30,   September 30, 
   2023   2022 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $19,000   $19,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $17,000   $19,000 
           
Weighted average remaining lease term – operating leases (in years)   1.3    2.3 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $95,000   $163,000 
           
Short-term operating lease liabilities  $68,000   $63,000 
Long-term operating lease liabilities   34,000    110,000 
Total operating lease liabilities  $102,000   $173,000 

  

 

 

 11 

 

 

Supplemental cash flow information related to the lease liabilities are as follows:

    
   Operating 
Year Ending June 30:  Lease 
2024 (remaining 9 months)  $59,000 
2025   47,000 
Total lease payments   106,000 
Less: Imputed interest/present value   (4,000)
Present value of lease liabilities  $102,000 

 

Note 5 – Related Party Transactions

 

Accrued Payroll and Payroll Taxes

 

In prior periods, the Company accrued salaries and estimated payroll taxes due to a former officer of the Company. As a June 30, 2023, total accrued payroll and payroll taxes-related parties amounted $280,000.

 

During the three months ended September 30, 2023, the Company accrued the payroll of an officer of the Company amounting to $46,000.

 

As of September 30, 2023, total accrued payroll and payroll taxes-related parties amounted to $326,000.

 

Note 6 – Notes Payable

 

In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and secured by all tangible and intangible property of the Company.

 

Pursuant to the terms of the SBA EIDL loan agreement, the Company is required to make monthly installment payments of approximately $700 starting in July 2021. However, the Company was not able to pay the required monthly installment due from July 2021 to April 2023.

 

In May 2023, the Company was able to cure the payment delay with the SBA and started paying the monthly installment due of approximately $700. As part of the agreement, all payments will be first applied to accrued interest until the Company becomes current with the interest due. At September 30, 2023 and September 30, 2022 approximately $13,000 of accrued interest is included in accounts payable and accrued expenses.

 

As of September 30, 2023 and June 30, 2023, the outstanding loan balance amounted to $150,000, respectively.

 

 

 

 12 

 

 

Note 7 - Stockholders' Equity

 

Stock Warrants

 

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2023 is as follows:

            
   Warrants  

Weighted-

Average

Exercise

Price

   Weighted-
Average
Remaining
Contractual
Life
(Years)		 
             
Outstanding at June 30, 2023   53,657,234   $0.09    1.82 
Granted   –    –    – 
Exercised   –    –    – 
Expired   –    –    – 
Outstanding at September 30, 2023 vested and exercisable   53,927,834   $0.09    1.57 

 

There was no intrinsic value of the outstanding warrants as of September 30, 2023, as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2023.

                                     
      Warrants Outstanding     Warrants Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                   
$ 0.03 - 0.05     11,126,518     3.04     $ 0.03     11,126,518       3.04  
  0.09     23,841,323     2.76       0.09     23,841,323       2.76  
$ 0.12     18,959,993     0.24     $ 0.12     18,959,993       0.24  
        53,927,834                   53,927,834          

 

 

 

 13 

 

 

Note 8 - Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, the Company entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary. In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary. The Company's President and Technology Development Supervisor both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2023.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the “Inventor”) to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2023 no patents have been granted in which this person is the legally named inventor.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 14 

 

 

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

 

Overview of our Business

 

Cavitation Technologies, Inc. ("CTi"), a Nevada corporation, was originally incorporated under the name Bio Energy, Inc. We design and engineer environmentally friendly technology-based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, algae oil extraction, biodiesel production, water-oil emulsions and crude oil yield enhancement.  Our systems are designed to process industrial liquids at a lower cost and higher yield than conventional technology. We are a process and product development firm that has developed, patented, and commercialized proprietary technology.

 

CTi has developed, patented, and commercialized proprietary technology that can be used for processing of industrial fluids. CTi's patented Nano Reactor® is the critical components of the CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in processing oils and fats. CTi has two issued patents relating to our Nano Reactor® systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, biodiesel production, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

 

We are engaged in manufacturing our Nano-Reactors, which are designed to help refine vegetable oils, biodiesel transesterification and treatment of produced and frack water. Our near-term goal is to continue to sell our systems through our partners, Desmet Ballestra and EW.

 

During the past several years we have developed a number of new applications utilizing the core principal of our technology. Our low pressure non-reactors (LPN) can be utilized in multiple industries that process large volumes of fluids and we anticipate accelerated commercial sales in our fiscal 2020. Further, we have miniaturized our non-reactors to be utilized in various consumer oriented products, such as, processing and enhancing spirits and wines, drinking water with infusion of vitamins, minerals and cannabidiol (CBD) oil.

 

We have agreements to license our technology globally through our strategic partners, Desmet Ballestra Group (Desmet) and Enviro Watertek, LLC (EW) and Alchemy Beverages, Inc (ABI). Desmet have been providing monthly advances of $50,000. We may need additional funding, and may attempt to raise additional debt and/or equity financing to fund operations and additional working capital. However, there is no assurance that we will be successful in obtaining such financing or obtained sufficient amounts necessary to meet our business needs, or that we will be able to meet our future contractual obligations.

 

Inflation

 

Global inflation also increased during 2022 and in 2023. The Russia and Ukraine conflict and other geopolitical conflicts, as well as related international response, have exacerbated inflationary pressures, including causing increases in the price for goods and services and global supply chain disruptions, which have resulted and may continue to result in shortages in food products, materials and services. Such shortages have resulted and may continue to result in inflationary cost increases for labor, fuel, food products, materials and services, and could continue to cause costs to increase as well as result in the scarcity of certain materials. We cannot predict any future trends in the rate of inflation or other negative economic factors or associated increases in our operating costs and how that may impact our business. To the extent we and our customers we service are unable to recover higher operating costs resulting from inflation or otherwise mitigate the impact of such costs on our and their business, our revenues and gross profit could decrease, and our financial condition and results of operations could be adversely affected.

 

 

 

 15 

 

 

Results of Operations

 

Results of Operations for the Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022

 

The following is a comparison of our results of operations for the three months ended September 30, 2023 and 2022.

 

   For the Three Months Ended         
   September 30,         
   2023   2022   $ Change   % Change 
                 
Revenue  $–   $244,000   $(244,000)   (100)%
Revenue from related party   –    17,000    (17,000)   (100)%
Cost of revenue   –    (50,000)   50,000    (100)%
Gross profit   –    211,000    (211,000)   (100)%
                     
General and administrative expenses   214,000    265,000    (51,000)   (19)%
Research and development expenses   36,000    –    36,000    100%
Total operating expenses   250,000    265,000    (15,000)   (6)%
Loss from operations   (250,000)   (54,000)   (196,000)   363%
(Loss) Income from equity method investment   –    (18,000)   18,000    (100)%
Interest expense   (1,000)   (1,000)   –    0%
Net loss  $(251,000)  $(73,000)  $(178,000)   244%

  

Revenue

 

The Company generates revenues from the sale of the Nano Reactor® to customers/distributor. Additionally, the Company generates revenues from its equity method investment, specifically fees from usage of reactors or usage fees.

 

During the three months ended September 30, 2023 we recorded no revenues compared to $244,000 for the three months ended September 30, 2022. Revenues decreased since the Company did not ship any purchase orders for Desmet during the current period compared to three purchase orders received in prior period. In addition, the Company also recognized usage fees of $17,000 during the prior period while none during the current period.

 

Cost of Revenue

 

During the three months ended September 30, 2023 and 2022, we recorded no cost of sales compared to $50,000 during the same period in prior year, which was the result of the revenue transactions described above.

 

Operating Expenses

 

Operating expenses for the three months ended September 30, 2023 amounted to $214,000 compared with $265,000 for the same period in 2022, a decrease of $51,000 or 19%. Decrease in general and administrative expense are related to salaries and professional fees.

 

 

 

 16 

 

 

Research and development (R&D) expenses for the three months ended September 30, 2023 and 2022 were $36,000 and $0, respectively. During the three months ended September 30, 2023, the Company began another R&D project consisting of the design and manufacture of an experimental installation for plasma activation of water by generating a plasma discharge in a water stream.

 

Other income (expense)

 

Other income (expense) for the three months ended September 30, 2023 amounted to $(1,000) of interest expense. For the three months ended September 30, 2022 other income (expense) amounted to $(1,000) of interest expense and loss from equity method investment of $(18,000).

 

Liquidity and Capital Resource

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $251,000 and had a stockholders’ deficit of $1,170,000 as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2023, the Company has cash in the amount of $140,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Cash Flow

 

Net cash provided by operating activities during the three months ended September 30, 2023 amounted to $122,000 compared to net cash used in operating activities of $74,000 for the same period in fiscal 2022. Funding for the operating activities was provided primarily by sales of our systems to Desmet, advances from distributor and cash reserve.

 

Critical Accounting Policies

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used for allowance for impairment analysis for property and equipment, accrual of potential liabilities, valuation allowance for deferred tax assets, and assumption in valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 

 

 17 

 

 

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Recently Issued Accounting Standards

 

See Note 1 of the Condensed Consolidated Financial Statements for a discussion of recently issued accounting standards.

 

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable for smaller reporting companies.

 

ITEM 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

In accordance with rule 13a-15(a), CTi management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

In accordance with Rule 13a-15(b) and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of September 30, 2023 the Company carried out an evaluation, under the supervision and with the participation of its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Company's principal executive officer and principal financial officer concluded that these disclosure controls and procedures were not effective as of September 30, 2023.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting during the first quarter of fiscal 2023 that have materially affected or are reasonably likely to materially affect the company's internal control over financial reporting.

 

 

 

 18 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures.

 

None

 

Item 5. Other Information.

 

None

 

 

 

 

 

 

 

 

 

 

 19 

 

 

Item 6. Exhibits, Financial Statement Schedules.

 

      Incorporated by Reference
Exhibit   Filed        
Number Exhibit Description Herewith Form Pd. Ending Exhibit Filing Date
             
3(i)(a) Articles of Incorporation - original name of Bioenergy, Inc.   SB-2 N/A 3.1 October 19, 2006
3(i)(b) Articles of Incorporation - Amended and Restated   10-Q December 31, 2008 3-1 February 17, 2009
3(i)(c) Articles of Incorporation - Amended and Restated   10-Q June 30, 2009 3-1 May 14, 2009
3(i)(d) Articles of Incorporation - Amended; increase in authorized shares   8-K N/A N/A October 29, 2009
3(i)(e) Articles of Incorporation - Certificate of Amendment; forward split   10-Q December 31, 2009 3-1 November 16, 2009
10.1 Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008   8-K June 30, 2009 10.1 May 18, 2010
10.2 Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008   8-K June 30, 2009 10.2 May 18, 2010
10.3 Assignment of Patent Assignment Agreement between the Company and Roman Gordon   8-K June 30, 2009 10.3 May 18, 2010
10.4 Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky   8-K June 30, 2009 10.4 May 18, 2010
10.5 Employment Agreement between the Company and Roman Gordon date March 17, 2008   10K/A June 30, 2009 10.3 October 20, 2011
10.6 Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008   10K/A June 30, 2009 10.4 October 20, 2011
10.7 Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008   10-Q December 31, 2010 10.3 February 11, 2011
10.8 Board of Director Agreement - James Fuller   10-Q December 31, 2011 10.12 October 20, 2011
10.9 Technology and License Agreement with Desmet Ballestra dated 14 May 2012   10-K June 30, 2012 10.1 October 15, 2012
10.10 Short Term Loan Agreement - CEO   10-K June 30, 2012 10.11 October 15, 2012
10.11 Loan Agreement - Desmet Ballestra - Oct. 26, 2010          
14.1 Code of Business Conduct and Ethics*   10-K June 30, 2011 14.1 September 28, 2011
31.1 Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
31.2 Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X        
32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X        
             
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) X        
101.SCH Inline XBRL Taxonomy Extension Schema Document X        
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X        
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X        
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X        
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X        
104 Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101)          

 

* In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our “Code of Business Conduct and Ethics”. A copy may be requested by sending an email to info@cavitationtechnologies.com.

 

 

 

 20 

 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN THE CAPACITIES AND ON THE DATES INDICATED

 

SIGNATURE   TITLE   DATE
         
         
/s/ N. Voloshin   President; Member of Board of Directors   November 1, 2023
N. Voloshin   (Principal Executive Officer)    
         
/s/ N. Voloshin   Chief Financial Officer   November 1, 2023
N. Voloshin   (Principal Financial Officer)    
         

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 21 

 

 EX-31.1 2 cavitation_ex3101.htm CERTIFICATION

Exhibit 31.1

 

Certification

 

I, N. Voloshin, certify that:

 

1. I have reviewed this quarterly report for the period ending September 30, 2023 on Form 10-Q of Cavitation Technologies, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 1, 2023 /s/ N. VOLOSHIN
  Name: N. Voloshin
  Title: Chief Executive Officer

 

 EX-31.2 3 cavitation_ex3102.htm CERTIFICATION

Exhibit 31.2

 

Certification

 

I, N. Voloshin, certify that:

 

1. I have reviewed this quarterly report for the period ending September 30, 2023 on Form 10-Q of Cavitation Technologies, Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 1, 2023 /s/ N. VOLOSHIN
  Name: N. Voloshin
  Title: Chief Financial Officer

 

 EX-32.1 4 cavitation_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION

 

I, N. Voloshin, Chief Executive Officer of Cavitation Technologies, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 1, 2023 /s/ N. VOLOSHIN
  Name: N. Voloshin
  Title: Chief Executive Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 5 cavitation_ex3202.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION

 

I, N. Voloshin, Principal Financial Officer of Cavitation Technologies, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 1, 2023 /s/ N. VOLOSHIN
  Name: N. Voloshin
  Title: Principal Financial Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 GRAPHIC 6 cavlogo.jpg GRAPHIC begin 644 cavlogo.jpg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end EX-101.SCH 7 cvat-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Contracts with Desmet Ballestra Group link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investment in equity method investment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Operating Lease link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Operating Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Contracts with Desmet Ballestra Group (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Investment in equity method investment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Operating Lease (Details - Lease Cost) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stockholders' Equity (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stockholders' Equity (Details - Warrants by exercise price) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cvat-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cvat-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cvat-20230930_lab.xml XBRL LABEL FILE Product and Service [Axis] Revenue From Customers [Member] Revenue From Joint Venture [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Customer [Axis] One Vendor [Member] Concentration Risk Benchmark [Axis] Accounts Payable [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Two Vendors [Member] Desmet [Member] Revenue Benchmark [Member] Customer Concentration Risk [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Nano Reactor Sales [Member] Investment, Name [Axis] Ameredev [Member] Long-Term Debt, Type [Axis] EIDL Loan [Member] Award Type [Axis] Exercise Price Range [Axis] $0.03-$0.05 [Member] $0.09 [Member] $0.12 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Total current assets Property and equipment, net Equity method investment Operating lease right of use asset, net Other assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses Accrued payroll and payroll taxes due to officers Note payable Operating lease liability, current portion Advances from distributor Total current liabilities Note payable, non-current Operating lease liability, non-current portion Total liabilities Commitments and contingencies Stockholders' deficit: Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively Common stock, $0.001 par value, 1,000,000,000 shares authorized, 284,289,740 shares issued and outstanding as of September 30, 2023 and June 30, 2023 Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Total revenue Cost of revenue Gross profit General and administrative expenses Research and development expenses Total operating expenses Loss from operations Other expense: Loss from equity method investment Interest expense Net Loss Income Statement [Abstract] Net Loss per share, Basic Net Loss per share, Diluted Weighted average shares outstanding, Basic Weighted average shares outstanding, Diluted Beginning balance, value Balance at beginning, shares Net loss Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] Net loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Gain on forgiveness of note payable Effect of changes in: Accounts receivable Operating lease right of use asset Accounts payable and accrued expenses Accrued payroll and payroll taxes due to officers Advances from distributor Operating lease liability Prepaid expenses Net cash provided by (used in) operating activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Summary of Significant Accounting Policies Contracts With Desmet Ballestra Group Contracts with Desmet Ballestra Group Equity Method Investments and Joint Ventures [Abstract] Investment in equity method investment Operating Lease Operating Lease Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders' Equity Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Basis of Presentation Going Concern Use of Estimates Revenue Recognition Equity Method Investment Net (Loss) Per Share Concentrations Fair Value Measurement Recent Accounting Pronouncements Schedule of antidilutive shares Schedule of lease expense Schedule of lease liabilities maturities Schedule of warrant activity Schedule of warrants outstanding and exercisable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares Schedule of Product Information [Table] Product Information [Line Items] Net loss Stockholders' deficit Cash Concentration risk percentage Revenue from Contract with Customer, Including Assessed Tax Periodic payment Customer advances Advances received Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Operating lease cost Cash paid for amounts included in the measurement of lease liabilities Weighted average remaining lease term - operating leases (in years) Average discount rate - operating leases Long-term right-of-use assets Short-term operating lease liabilities Long-term operating lease liabilities Total operating lease liabilities 2024 (remaining 9 months) 2025 Total lease payments Less: Imputed interest/present value Present value of lease liabilities Employee-related liabilities Accrued payroll Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Proceeds from Loans Debt Instrument, Interest Rate, Stated Percentage Interest Payable Notes Payable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Warrants outstanding, beginning balance Weighted average exercise price, warrants outstanding, beginning price Weighted average remaining contractual life Warrants granted Weighted average exercise price, granted Warrants exercised Weighted average exercise price, exercised Warrants expired Weighted average exercise price, expired Warrants vested and exercisable Weighted average exercise price, vested and exercisable Weighted average remaining contractual life, exercisable and vested Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number of warrant shares outstanding Weighted average remaining life warrants outstanding Number of warrant shares exercisable Weighted average remaining life warrants exercisable Number of warrant shares exercisable Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Cost of Revenue Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Net Income (Loss) Attributable to Parent Shares, Outstanding Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Prepaid Expenses, Other Net Cash Provided by (Used in) Operating Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Lessee, Operating Leases [Text Block] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Notes Payable [Default Label] Class of Warrant or Right, Exercise Price of Warrants or Rights EX-101.PRE 11 cvat-20230930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 3 Months Ended
Sep. 30, 2023
Oct. 31, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --06-30  
Entity File Number 000-53239  
Entity Registrant Name Cavitation Technologies, Inc.  
Entity Central Index Key 0001376793  
Entity Tax Identification Number 20-4907818  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 10019 CANOGA AVENUE  
Entity Address, City or Town CHATSWORTH  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91311  
City Area Code (818)  
Local Phone Number 718-0905  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   284,289,740
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 140,000 $ 18,000
Total current assets 140,000 18,000
Property and equipment, net 1,000 1,000
Equity method investment 1,000 1,000
Operating lease right of use asset, net 95,000 113,000
Other assets 10,000 10,000
Total assets 247,000 143,000
Current liabilities:    
Accounts payable and accrued expenses 144,000 120,000
Accrued payroll and payroll taxes due to officers 326,000 280,000
Note payable 5,000 5,000
Operating lease liability, current portion 68,000 68,000
Advances from distributor 695,000 391,000
Total current liabilities 1,238,000 864,000
Note payable, non-current 145,000 145,000
Operating lease liability, non-current portion 34,000 53,000
Total liabilities 1,417,000 1,062,000
Commitments and contingencies
Stockholders' deficit:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively 0 0
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 284,289,740 shares issued and outstanding as of September 30, 2023 and June 30, 2023 284,000 284,000
Additional paid-in capital 26,083,000 26,083,000
Accumulated deficit (27,537,000) (27,286,000)
Total stockholders' deficit (1,170,000) (919,000)
Total liabilities and stockholders' deficit $ 247,000 $ 143,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2023
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 284,289,740 284,289,740
Common stock, shares outstanding 284,289,740 284,289,740
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Total revenue $ 0 $ 261,000
Cost of revenue 0 (50,000)
Gross profit 0 211,000
General and administrative expenses 214,000 265,000
Research and development expenses 36,000 0
Total operating expenses 250,000 265,000
Loss from operations (250,000) (54,000)
Other expense:    
Loss from equity method investment 0 (18,000)
Interest expense (1,000) (1,000)
Net Loss (251,000) (73,000)
Revenue From Customers [Member]    
Total revenue 0 244,000
Revenue From Joint Venture [Member]    
Total revenue $ 0 $ 17,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net Loss per share, Basic $ (0.00) $ (0.00)
Net Loss per share, Diluted $ (0.00) $ (0.00)
Weighted average shares outstanding, Basic 284,289,740 276,698,831
Weighted average shares outstanding, Diluted 284,289,740 276,698,831
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Jun. 30, 2022 $ 277,000 $ 26,005,000 $ (25,246,000) $ 1,036,000
Balance at beginning, shares at Jun. 30, 2022 276,698,831      
Net loss (73,000) (73,000)
Ending balance, value at Sep. 30, 2022 $ 272,000 25,810,000 (25,319,000) 963,000
Balance at ending, shares at Sep. 30, 2022 272,701,844      
Beginning balance, value at Jun. 30, 2023 $ 284,000 26,083,000 (27,286,000) (919,000)
Balance at beginning, shares at Jun. 30, 2023 284,289,740      
Net loss (251,000) (251,000)
Ending balance, value at Sep. 30, 2023 $ 284,000 $ 26,083,000 $ (27,537,000) $ (1,170,000)
Balance at ending, shares at Sep. 30, 2023 284,289,740      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Statement of Cash Flows [Abstract]      
Net loss $ (251,000) $ (73,000)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Gain on forgiveness of note payable 0 18,000  
Effect of changes in:      
Accounts receivable 0 (17,000)  
Operating lease right of use asset 18,000 17,000  
Accounts payable and accrued expenses 24,000 4,000  
Accrued payroll and payroll taxes due to officers 46,000 0 $ 46,000
Advances from distributor 304,000 (44,000)  
Operating lease liability (19,000) (17,000)  
Prepaid expenses 0 38,000  
Net cash provided by (used in) operating activities 122,000 (74,000)  
Net increase (decrease) in cash and cash equivalents 122,000 (74,000)  
Cash and cash equivalents, beginning of period 18,000 441,000  
Cash and cash equivalents, end of period 140,000 367,000 $ 140,000
Supplemental disclosures of cash flow information:      
Cash paid for interest 2,000 0  
Cash paid for income taxes $ 0 $ 0  
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Summary of Significant Accounting Policies
 3 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Summary of Significant Accounting Policies

Note 1 - Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America (“U.S.”) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2023 are not indicative of the results that may be expected for the fiscal year ending June 30, 2024. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2023 filed on October 3, 2023. The condensed consolidated balance sheet as of June 30, 2023 has been derived from the audited financial statements included in the Form 10-K for that year.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $251,000 and had a stockholders’ deficit of $1,170,000 as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2023, the Company has cash in the amount of $140,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of September 30, 2023 and June 30, 2023, the carrying value of its equity method investments was $1,000 for both periods presented.

 

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

There were no adjustments to net (loss) required for purposes of computing diluted earnings per share. At September 30, 2023 and September 30, 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive.

        
   September 30, 2023   June 30, 2023 
Options   –    1,250,000 
Warrants   53,657,234    53,657,234 

 

Concentrations

 

Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.

 

Accounts Payable and Accrued Expenses – two vendors accounted for 22% and 30% of accounts payable and accrued expenses as of September 30, 2023, respectively. Two vendors accounted for 52% and 36% of accounts payable and accrued expenses as of June 30, 2023.

 

Revenues – during the three-month period ended September 30, 2022, 93% of revenues were from Desmet.

 

Fair Value Measurement

 

FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

  · Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
     
  · Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
     
  · Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2023 and June 30, 2023, the fair values of cash and cash equivalents, accounts payable and accrued expenses, and accrued payroll and payroll taxes approximate their carrying values due to their short-term nature.

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Contracts with Desmet Ballestra Group
 3 Months Ended
Sep. 30, 2023
Contracts With Desmet Ballestra Group  
Contracts with Desmet Ballestra Group

Note 2 - Contracts with Desmet Ballestra Group

 

October 2021, the Company executed a three-year agreement with Desmet Ballestra (Desmet), a company located in Europe. This agreement is a continuation of the October 2018 agreement that expired also in October 2021. In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet.

 

During the three months ended September 30, 2022, the Company recorded sales of $244,000 from Nano Reactor® sales from Desmet.

 

During the three months ended September 30, 2023 there were no sales from Nano Reactor to Desmet.

 

As part of the October 2021 agreement with Desmet, the Company also receives cash advances of $40,000 per month, subject to certain limitations, as advance payment for the sale of reactors. The Company initially records the advances received as “advances from distributor” a liability account, until such time revenue recognition is met. As of June 30, 2023, outstanding balance of customer advances amounted to $391,000.

 

During the three months ended September 30, 2023, advances received from Desmet amounted to $304,000.

 

As of September 30, 2023, outstanding advances from Desmet amounted to $695,000.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Investment in equity method investment
 3 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Investment in equity method investment

Note 3 - Investment in equity method investment

 

In April 2019, the Company and an unrelated entity, Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method in accordance with ASC 323 as the Company’s investments in Enviro, an unconsolidated entity and for which it has the ability to exercise significant influence but not control. From inception up to June 30, 2023, Enviro had no operations.

 

In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.

 

As of September 30, 2023 and June 30, 2023, the balance of the equity method investment amounted to $1,000, for both periods presented.

 

During the three months ended September 30, 2022, the Company recognized a loss of $17,000 related to the equity method investment. There was no similar transaction during the period ended September 30, 2023

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Lease
 3 Months Ended
Sep. 30, 2023
Operating Lease  
Operating Lease

Note 4 – Operating Lease

 

The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.

 

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

        
   September 30,   September 30, 
   2023   2022 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $19,000   $19,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $17,000   $19,000 
           
Weighted average remaining lease term – operating leases (in years)   1.3    2.3 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $95,000   $163,000 
           
Short-term operating lease liabilities  $68,000   $63,000 
Long-term operating lease liabilities   34,000    110,000 
Total operating lease liabilities  $102,000   $173,000 

  

Supplemental cash flow information related to the lease liabilities are as follows:

    
   Operating 
Year Ending June 30:  Lease 
2024 (remaining 9 months)  $59,000 
2025   47,000 
Total lease payments   106,000 
Less: Imputed interest/present value   (4,000)
Present value of lease liabilities  $102,000 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
 3 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 5 – Related Party Transactions

 

Accrued Payroll and Payroll Taxes

 

In prior periods, the Company accrued salaries and estimated payroll taxes due to a former officer of the Company. As a June 30, 2023, total accrued payroll and payroll taxes-related parties amounted $280,000.

 

During the three months ended September 30, 2023, the Company accrued the payroll of an officer of the Company amounting to $46,000.

 

As of September 30, 2023, total accrued payroll and payroll taxes-related parties amounted to $326,000.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable
 3 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Notes Payable

Note 6 – Notes Payable

 

In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and secured by all tangible and intangible property of the Company.

 

Pursuant to the terms of the SBA EIDL loan agreement, the Company is required to make monthly installment payments of approximately $700 starting in July 2021. However, the Company was not able to pay the required monthly installment due from July 2021 to April 2023.

 

In May 2023, the Company was able to cure the payment delay with the SBA and started paying the monthly installment due of approximately $700. As part of the agreement, all payments will be first applied to accrued interest until the Company becomes current with the interest due. At September 30, 2023 and September 30, 2022 approximately $13,000 of accrued interest is included in accounts payable and accrued expenses.

 

As of September 30, 2023 and June 30, 2023, the outstanding loan balance amounted to $150,000, respectively.

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
 3 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Equity

Note 7 - Stockholders' Equity

 

Stock Warrants

 

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2023 is as follows:

            
   Warrants  

Weighted-

Average

Exercise

Price

   Weighted-
Average
Remaining
Contractual
Life
(Years)		 
             
Outstanding at June 30, 2023   53,657,234   $0.09    1.82 
Granted   –    –    – 
Exercised   –    –    – 
Expired   –    –    – 
Outstanding at September 30, 2023 vested and exercisable   53,927,834   $0.09    1.57 

 

There was no intrinsic value of the outstanding warrants as of September 30, 2023, as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2023.

                                     
      Warrants Outstanding     Warrants Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                   
$ 0.03 - 0.05     11,126,518     3.04     $ 0.03     11,126,518       3.04  
  0.09     23,841,323     2.76       0.09     23,841,323       2.76  
$ 0.12     18,959,993     0.24     $ 0.12     18,959,993       0.24  
        53,927,834                   53,927,834          

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 3 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 8 - Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, the Company entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary. In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary. The Company's President and Technology Development Supervisor both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2023.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the “Inventor”) to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2023 no patents have been granted in which this person is the legally named inventor.

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America (“U.S.”) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2023 are not indicative of the results that may be expected for the fiscal year ending June 30, 2024. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2023 filed on October 3, 2023. The condensed consolidated balance sheet as of June 30, 2023 has been derived from the audited financial statements included in the Form 10-K for that year.

 
Going Concern

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $251,000 and had a stockholders’ deficit of $1,170,000 as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of September 30, 2023, the Company has cash in the amount of $140,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 
Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

 
Revenue Recognition

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 
Equity Method Investment

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of September 30, 2023 and June 30, 2023, the carrying value of its equity method investments was $1,000 for both periods presented.

 
Net (Loss) Per Share

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

There were no adjustments to net (loss) required for purposes of computing diluted earnings per share. At September 30, 2023 and September 30, 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive.

        
   September 30, 2023   June 30, 2023 
Options   –    1,250,000 
Warrants   53,657,234    53,657,234 

 
Concentrations

Concentrations

 

Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.

 

Accounts Payable and Accrued Expenses – two vendors accounted for 22% and 30% of accounts payable and accrued expenses as of September 30, 2023, respectively. Two vendors accounted for 52% and 36% of accounts payable and accrued expenses as of June 30, 2023.

 

Revenues – during the three-month period ended September 30, 2022, 93% of revenues were from Desmet.

 
Fair Value Measurement

Fair Value Measurement

 

FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

The three levels of the fair value hierarchy are as follows:

 

  · Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
     
  · Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
     
  · Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

On September 30, 2023 and June 30, 2023, the fair values of cash and cash equivalents, accounts payable and accrued expenses, and accrued payroll and payroll taxes approximate their carrying values due to their short-term nature.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of antidilutive shares
        
   September 30, 2023   June 30, 2023 
Options   –    1,250,000 
Warrants   53,657,234    53,657,234 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Lease (Tables)
 3 Months Ended
Sep. 30, 2023
Operating Lease  
Schedule of lease expense
        
   September 30,   September 30, 
   2023   2022 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $19,000   $19,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $17,000   $19,000 
           
Weighted average remaining lease term – operating leases (in years)   1.3    2.3 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $95,000   $163,000 
           
Short-term operating lease liabilities  $68,000   $63,000 
Long-term operating lease liabilities   34,000    110,000 
Total operating lease liabilities  $102,000   $173,000 
Schedule of lease liabilities maturities
    
   Operating 
Year Ending June 30:  Lease 
2024 (remaining 9 months)  $59,000 
2025   47,000 
Total lease payments   106,000 
Less: Imputed interest/present value   (4,000)
Present value of lease liabilities  $102,000 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
 3 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of warrant activity
            
   Warrants  

Weighted-

Average

Exercise

Price

   Weighted-
Average
Remaining
Contractual
Life
(Years)		 
             
Outstanding at June 30, 2023   53,657,234   $0.09    1.82 
Granted   –    –    – 
Exercised   –    –    – 
Expired   –    –    – 
Outstanding at September 30, 2023 vested and exercisable   53,927,834   $0.09    1.57 
Schedule of warrants outstanding and exercisable
                                     
      Warrants Outstanding     Warrants Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                   
$ 0.03 - 0.05     11,126,518     3.04     $ 0.03     11,126,518       3.04  
  0.09     23,841,323     2.76       0.09     23,841,323       2.76  
$ 0.12     18,959,993     0.24     $ 0.12     18,959,993       0.24  
        53,927,834                   53,927,834          
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Summary of Significant Accounting Policies (Details) - shares
 3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 0 1,250,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 53,657,234 53,657,234
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Product Information [Line Items]        
Net loss $ 251,000 $ 73,000    
Stockholders' deficit 1,170,000 $ (963,000) $ 919,000 $ (1,036,000)
Cash 140,000   18,000  
Equity method investment $ 1,000   $ 1,000  
One Vendor [Member] | Accounts Payable [Member] | Product Concentration Risk [Member]        
Product Information [Line Items]        
Concentration risk percentage 22.00%   52.00%  
Two Vendors [Member] | Accounts Payable [Member] | Product Concentration Risk [Member]        
Product Information [Line Items]        
Concentration risk percentage 30.00%   36.00%  
Desmet [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration risk percentage   93.00%    
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Contracts with Desmet Ballestra Group (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Oct. 30, 2021
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Periodic payment $ 40,000      
Customer advances   $ 695,000   $ 391,000
Desmet [Member]        
Advances received   304,000    
Desmet [Member] | Nano Reactor Sales [Member]        
Revenue from Contract with Customer, Including Assessed Tax   $ 0 $ 244,000  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Investment in equity method investment (Details Narrative) - USD ($)
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Schedule of Equity Method Investments [Line Items]      
Equity method investment $ 1,000   $ 1,000
Loss from equity method investment 0 $ (18,000)  
Ameredev [Member]      
Schedule of Equity Method Investments [Line Items]      
Loss from equity method investment $ 0 $ 17,000  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Lease (Details - Lease Cost) - USD ($)
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Operating Lease      
Operating lease cost $ 19,000 $ 19,000  
Cash paid for amounts included in the measurement of lease liabilities $ 17,000 $ 19,000  
Weighted average remaining lease term - operating leases (in years) 1 year 3 months 18 days 2 years 3 months 18 days  
Average discount rate - operating leases 4.00% 4.00%  
Long-term right-of-use assets $ 95,000 $ 163,000 $ 113,000
Short-term operating lease liabilities 68,000 63,000 68,000
Long-term operating lease liabilities 34,000 110,000 $ 53,000
Total operating lease liabilities $ 102,000 $ 173,000  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Lease (Details - Operating Lease Minimum payments) - USD ($)
Sep. 30, 2023
Sep. 30, 2022
Operating Lease    
2024 (remaining 9 months) $ 59,000  
2025 47,000  
Total lease payments 106,000  
Less: Imputed interest/present value (4,000)  
Present value of lease liabilities $ 102,000 $ 173,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Jun. 30, 2023
Related Party Transactions [Abstract]        
Employee-related liabilities $ 326,000   $ 326,000 $ 280,000
Accrued payroll $ 46,000 $ 0 $ 46,000  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable (Details Narrative) - USD ($)
 1 Months Ended
Jul. 31, 2020
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Debt Instrument [Line Items]        
Notes Payable     $ 150,000  
EIDL Loan [Member]        
Debt Instrument [Line Items]        
Proceeds from Loans $ 150,000      
Debt Instrument, Interest Rate, Stated Percentage 3.75%      
Interest Payable   $ 13,000   $ 13,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Details - Warrant activity) - Warrant [Member]
 3 Months Ended
Sep. 30, 2023
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Warrants outstanding, beginning balance | shares 53,657,234
Weighted average exercise price, warrants outstanding, beginning price | $ / shares $ 0.09
Weighted average remaining contractual life 1 year 9 months 25 days
Warrants granted | shares 0
Weighted average exercise price, granted | $ / shares $ 0
Warrants exercised | shares 0
Weighted average exercise price, exercised | $ / shares $ 0
Warrants expired | shares 0
Weighted average exercise price, expired | $ / shares $ 0
Warrants vested and exercisable | shares 53,927,834
Weighted average exercise price, vested and exercisable | $ / shares $ 0.09
Weighted average remaining contractual life, exercisable and vested 1 year 6 months 25 days
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Details - Warrants by exercise price) - shares
 3 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Warrant [Member]    
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Number of warrant shares outstanding 53,927,834 53,657,234
Weighted average remaining life warrants outstanding 1 year 9 months 25 days  
Number of warrant shares exercisable 53,927,834  
$0.03-$0.05 [Member]    
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Number of warrant shares outstanding 11,126,518  
Weighted average remaining life warrants outstanding 3 years 14 days  
Number of warrant shares exercisable 11,126,518  
Weighted average remaining life warrants exercisable 3 years 14 days  
$0.09 [Member]    
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Number of warrant shares outstanding 23,841,323  
Weighted average remaining life warrants outstanding 2 years 9 months 3 days  
Number of warrant shares exercisable 23,841,323  
Weighted average remaining life warrants exercisable 2 years 9 months 3 days  
$0.12 [Member]    
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Number of warrant shares outstanding 18,959,993  
Weighted average remaining life warrants outstanding 2 months 26 days  
Number of warrant shares exercisable 18,959,993  
Weighted average remaining life warrants exercisable 2 months 26 days  
XML 41 cavitation_i10q-093023_htm.xml IDEA: XBRL DOCUMENT 0001376793 2023-07-01 2023-09-30 0001376793 2023-10-31 0001376793 2023-09-30 0001376793 2023-06-30 0001376793 CVAT:RevenueFromCustomersMember 2023-07-01 2023-09-30 0001376793 CVAT:RevenueFromCustomersMember 2022-07-01 2022-09-30 0001376793 CVAT:RevenueFromJointVentureMember 2023-07-01 2023-09-30 0001376793 CVAT:RevenueFromJointVentureMember 2022-07-01 2022-09-30 0001376793 2022-07-01 2022-09-30 0001376793 us-gaap:CommonStockMember 2023-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001376793 us-gaap:RetainedEarningsMember 2023-06-30 0001376793 us-gaap:CommonStockMember 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2022-06-30 0001376793 2022-06-30 0001376793 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001376793 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001376793 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001376793 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001376793 us-gaap:CommonStockMember 2023-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001376793 us-gaap:RetainedEarningsMember 2023-09-30 0001376793 us-gaap:CommonStockMember 2022-09-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001376793 us-gaap:RetainedEarningsMember 2022-09-30 0001376793 2022-09-30 0001376793 CVAT:OneVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001376793 CVAT:TwoVendorsMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001376793 CVAT:OneVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0001376793 CVAT:TwoVendorsMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0001376793 CVAT:DesmetMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001376793 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001376793 us-gaap:StockOptionMember 2022-07-01 2023-06-30 0001376793 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001376793 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001376793 CVAT:DesmetMember CVAT:NanoReactorSalesMember 2022-07-01 2022-09-30 0001376793 CVAT:DesmetMember CVAT:NanoReactorSalesMember 2023-07-01 2023-09-30 0001376793 2021-10-01 2021-10-30 0001376793 CVAT:DesmetMember 2023-07-01 2023-09-30 0001376793 CVAT:AmeredevMember 2022-07-01 2022-09-30 0001376793 CVAT:AmeredevMember 2023-07-01 2023-09-30 0001376793 2023-01-01 2023-09-30 0001376793 CVAT:EIDLLoanMember 2020-07-01 2020-07-31 0001376793 CVAT:EIDLLoanMember 2020-07-31 0001376793 CVAT:EIDLLoanMember 2023-09-30 0001376793 CVAT:EIDLLoanMember 2022-09-30 0001376793 us-gaap:WarrantMember 2023-06-30 0001376793 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001376793 us-gaap:WarrantMember 2023-09-30 0001376793 CVAT:WarrantPrice1Member 2023-09-30 0001376793 CVAT:WarrantPrice1Member 2023-07-01 2023-09-30 0001376793 CVAT:WarrantPrice2Member 2023-09-30 0001376793 CVAT:WarrantPrice2Member 2023-07-01 2023-09-30 0001376793 CVAT:WarrantPrice3Member 2023-09-30 0001376793 CVAT:WarrantPrice3Member 2023-07-01 2023-09-30 iso4217:USD shares iso4217:USD shares pure 0001376793 false --06-30 2024 Q1 10-Q true false 2023-09-30 000-53239 Cavitation Technologies, Inc. NV 20-4907818 10019 CANOGA AVENUE CHATSWORTH CA 91311 (818) 718-0905 Yes Yes Non-accelerated Filer true false false 284289740 140000 18000 140000 18000 1000 1000 1000 1000 95000 113000 10000 10000 247000 143000 144000 120000 326000 280000 5000 5000 68000 68000 695000 391000 1238000 864000 145000 145000 34000 53000 1417000 1062000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 1000000000 1000000000 284289740 284289740 284289740 284289740 284000 284000 26083000 26083000 -27537000 -27286000 -1170000 -919000 247000 143000 0 244000 0 17000 0 261000 -0 50000 0 211000 214000 265000 36000 0 250000 265000 -250000 -54000 0 -18000 1000 1000 -251000 -73000 -0.00 -0.00 -0.00 -0.00 284289740 284289740 276698831 276698831 284289740 284000 26083000 -27286000 -919000 -251000 -251000 284289740 284000 26083000 -27537000 -1170000 276698831 277000 26005000 -25246000 1036000 -73000 -73000 272701844 272000 25810000 -25319000 963000 -251000 -73000 -0 -18000 -0 17000 18000 17000 24000 4000 46000 0 304000 -44000 -19000 -17000 -0 -38000 122000 -74000 122000 -74000 18000 441000 140000 367000 2000 0 0 0 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zRp8Fa9zMSqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - <span id="xdx_829_zrS0x7pPQdJ7">Organization and Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAb6Xe9sjOxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_860_zDCsPJ6cS5Wd">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America (“U.S.”) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2023 are not indicative of the results that may be expected for the fiscal year ending June 30, 2024. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2023 filed on October 3, 2023. The condensed consolidated balance sheet as of June 30, 2023 has been derived from the audited financial statements included in the Form 10-K for that year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--GoingConcernPolicyTextBlock_zTdLXKkqcKw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86E_zJMS33qFdsta">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20230930_zZdcE4PmQ8gj" title="Net loss">251,000</span> and had a stockholders’ deficit of $<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20230930_zf1S7k5baRje" title="Stockholders' deficit">1,170,000</span> as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company has cash in the amount of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230930_zRTHNzgngBLd" title="Cash">140,000</span>. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--UseOfEstimates_zPR4Rf7ynKne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zp0GXA0jIc26">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_z8wcDQkiWjSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_z4euWDBn1bS6">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zICLfuRQYFek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zX4xZ1jHHOpk">Equity Method Investment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of September 30, 2023 and June 30, 2023, the carrying value of its equity method investments was $<span id="xdx_90F_eus-gaap--EquityMethodInvestments_iI_c20230930_zv57QuqLbeb2" title="Equity method investment"><span id="xdx_902_eus-gaap--EquityMethodInvestments_iI_c20230630_zC9AIqAtxj74" title="Equity method investment">1,000</span></span> for both periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zjIJmFh2xJt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_862_zp7W0CxJQbS9">Net (Loss) Per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no adjustments to net (loss) required for purposes of computing diluted earnings per share. At September 30, 2023 and September 30, 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive.</p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWVm6dYWUO69" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zApQzbUDqqA9" style="display: none">Schedule of antidilutive shares</span></td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9yoOabSnHdh" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zDdq2Vz7xT64" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwndVhnExAA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmq1At4lqUob" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zD6kYA4Qa3ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zyB5FMKGIol9">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts Payable and Accrued Expenses – two vendors accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKS7uysbteyf" title="Concentration risk percentage">22</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--TwoVendorsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKroutOIvmih" title="Concentration risk percentage">30</span>% of accounts payable and accrued expenses as of September 30, 2023, respectively. Two vendors accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zoq24qOdMHOj" title="Concentration risk percentage">52</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--TwoVendorsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYyU68Q5IWU6" title="Concentration risk percentage">36</span>% of accounts payable and accrued expenses as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues – during the three-month period ended September 30, 2022, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1twHZFFbscj" title="Concentration risk percentage">93</span>% of revenues were from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaK0AqcjLMQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_z12G9PtUcPa">Fair Value Measurement</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The three levels of the fair value hierarchy are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2023 and June 30, 2023, the fair values of cash and cash equivalents, accounts payable and accrued expenses, and accrued payroll and payroll taxes approximate their carrying values due to their short-term nature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztOv8kaPOm3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zj833cidH9Va">Recent Accounting Pronouncements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAb6Xe9sjOxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_860_zDCsPJ6cS5Wd">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America (“U.S.”) and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2023 are not indicative of the results that may be expected for the fiscal year ending June 30, 2024. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2023 filed on October 3, 2023. The condensed consolidated balance sheet as of June 30, 2023 has been derived from the audited financial statements included in the Form 10-K for that year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--GoingConcernPolicyTextBlock_zTdLXKkqcKw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86E_zJMS33qFdsta">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the three months ended September 30, 2023, the Company incurred a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20230930_zZdcE4PmQ8gj" title="Net loss">251,000</span> and had a stockholders’ deficit of $<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20230930_zf1S7k5baRje" title="Stockholders' deficit">1,170,000</span> as of September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s June 30, 2023, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company has cash in the amount of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230930_zRTHNzgngBLd" title="Cash">140,000</span>. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect. The Company believes it has enough cash to sustain operations through December, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> -251000 -1170000 140000 <p id="xdx_845_eus-gaap--UseOfEstimates_zPR4Rf7ynKne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zp0GXA0jIc26">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in impairment analysis for fixed assets, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_z8wcDQkiWjSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_z4euWDBn1bS6">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zICLfuRQYFek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zX4xZ1jHHOpk">Equity Method Investment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. As of September 30, 2023 and June 30, 2023, the carrying value of its equity method investments was $<span id="xdx_90F_eus-gaap--EquityMethodInvestments_iI_c20230930_zv57QuqLbeb2" title="Equity method investment"><span id="xdx_902_eus-gaap--EquityMethodInvestments_iI_c20230630_zC9AIqAtxj74" title="Equity method investment">1,000</span></span> for both periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> 1000 1000 <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zjIJmFh2xJt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_862_zp7W0CxJQbS9">Net (Loss) Per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no adjustments to net (loss) required for purposes of computing diluted earnings per share. At September 30, 2023 and September 30, 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive.</p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWVm6dYWUO69" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zApQzbUDqqA9" style="display: none">Schedule of antidilutive shares</span></td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9yoOabSnHdh" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zDdq2Vz7xT64" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwndVhnExAA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmq1At4lqUob" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWVm6dYWUO69" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zApQzbUDqqA9" style="display: none">Schedule of antidilutive shares</span></td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9yoOabSnHdh" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zDdq2Vz7xT64" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwndVhnExAA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zmq1At4lqUob" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">53,657,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 1250000 53657234 53657234 <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zD6kYA4Qa3ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zyB5FMKGIol9">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts Payable and Accrued Expenses – two vendors accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKS7uysbteyf" title="Concentration risk percentage">22</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__srt--MajorCustomersAxis__custom--TwoVendorsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zKroutOIvmih" title="Concentration risk percentage">30</span>% of accounts payable and accrued expenses as of September 30, 2023, respectively. Two vendors accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zoq24qOdMHOj" title="Concentration risk percentage">52</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--TwoVendorsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYyU68Q5IWU6" title="Concentration risk percentage">36</span>% of accounts payable and accrued expenses as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues – during the three-month period ended September 30, 2022, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20220930__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1twHZFFbscj" title="Concentration risk percentage">93</span>% of revenues were from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.22 0.30 0.52 0.36 0.93 <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaK0AqcjLMQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_z12G9PtUcPa">Fair Value Measurement</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The three levels of the fair value hierarchy are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2023 and June 30, 2023, the fair values of cash and cash equivalents, accounts payable and accrued expenses, and accrued payroll and payroll taxes approximate their carrying values due to their short-term nature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztOv8kaPOm3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zj833cidH9Va">Recent Accounting Pronouncements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_804_ecustom--ContractWithDesmetBallestraTextBlock_zKm2lODYxeaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - <span id="xdx_824_zraDuLE23ASb">Contracts with Desmet Ballestra Group</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 2021, the Company executed a three-year agreement with Desmet Ballestra (Desmet), a company located in Europe. This agreement is a continuation of the October 2018 agreement that expired also in October 2021. In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2022, the Company recorded sales of $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20220701__20220930__srt--MajorCustomersAxis__custom--DesmetMember__srt--ProductOrServiceAxis__custom--NanoReactorSalesMember_z1QCTbpjNxKc">244,000 </span>from <i>Nano Reactor®</i> sales from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2023 there were <span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_do_c20230701__20230930__srt--MajorCustomersAxis__custom--DesmetMember__srt--ProductOrServiceAxis__custom--NanoReactorSalesMember_zHMw2n7goLR7">no</span> sales from Nano Reactor to Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the October 2021 agreement with Desmet, the Company also receives cash advances of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20211001__20211030_zL8sIqTNPMj4" title="Periodic payment">40,000</span> per month, subject to certain limitations, as advance payment for the sale of reactors. The Company initially records the advances received as “advances from distributor” a liability account, until such time revenue recognition is met. As of June 30, 2023, outstanding balance of customer advances amounted to $<span id="xdx_907_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pp0p0_c20230630_zYAOhppz69ze" title="Customer advances">391,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2023, advances received from Desmet amounted to $<span id="xdx_906_eus-gaap--ProceedsFromDepositsFromCustomers_pp0p0_c20230701__20230930__srt--MajorCustomersAxis__custom--DesmetMember_zzo090TxhBch" title="Advances received">304,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, outstanding advances from Desmet amounted to $<span id="xdx_905_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pp0p0_c20230930_zenjrb8uIYU4" title="Customer advances">695,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 244000 0 40000 391000 304000 695000 <p id="xdx_80B_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zvY8L4JrLpP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - <span id="xdx_823_zqyzTMC4sYn8">Investment in equity method investment</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, the Company and an unrelated entity, Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method in accordance with ASC 323 as the Company’s investments in Enviro, an unconsolidated entity and for which it has the ability to exercise significant influence but not control. From inception up to June 30, 2023, Enviro had no operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023 and June 30, 2023, the balance of the equity method investment amounted to $<span id="xdx_909_eus-gaap--EquityMethodInvestments_iI_c20230930_zw8bi6KYU1l8" title="Equity method investment"><span id="xdx_908_eus-gaap--EquityMethodInvestments_iI_c20230630_zsPmHMNjtqma" title="Equity method investment">1,000</span></span>, for both periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2022, the Company recognized a loss of $<span id="xdx_902_eus-gaap--IncomeLossFromEquityMethodInvestments_pp0p0_c20220701__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zGPt75vJURv2" title="Loss from equity method investment">17,000</span> related to the equity method investment. There was <span id="xdx_90D_eus-gaap--IncomeLossFromEquityMethodInvestments_pp0p0_do_c20230701__20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zptRkGPDDlLe" title="Loss from equity method investment">no</span> similar transaction during the period ended September 30, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1000 1000 17000 0 <p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_z4t6gF9rTPxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 – <span id="xdx_822_zbNbVTIcLXE6">Operating Lease</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of lease expense and supplemental cash flow information related to leases for the period are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zG9PmHD9XCw" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Lease Cost)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zLsBuNLVlHM2" style="display: none">Schedule of lease expense</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; width: 68%; text-align: left">Operating lease (included in general and administrative in the Company’s consolidated statement of operations)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseCost_pp0p0_c20230701__20230930_z5Z6Dspegv2d" style="width: 13%; text-align: right" title="Operating lease cost">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220701__20220930_zSJaDIryQItg" style="width: 13%; text-align: right" title="Operating lease cost">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeasePaymentsUse_pp0p0_c20230701__20230930_ztwJoNuVNRki" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">17,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePaymentsUse_pp0p0_c20220701__20220930_zKxCov15cJef" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">19,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zQdKkV78smFi" title="Weighted average remaining lease term - operating leases (in years)">1.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220930_zcQfG5h9kX55" title="Weighted average remaining lease term - operating leases (in years)">2.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230930_zBWVs8jATejb" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220930_zCEioJ51cHSf" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left">The supplemental balance sheet information related to leases for the period is as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Long-term right-of-use assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230930_zN0kBp4VWf8j" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">95,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220930_zvCDpjfTJnqj" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">163,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Short-term operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230930_zMgXJ4qVYDKh" style="text-align: right" title="Short-term operating lease liabilities">68,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220930_z8FDKX9lxsGa" style="text-align: right" title="Short-term operating lease liabilities">63,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230930_zt7Sw9yKfqwe" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">34,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220930_zvl7xlSAJBO6" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">110,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20230930_zy9FbkYJ58ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">102,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20220930_zXOZfsuy7SSe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">173,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zCFVsTzUuafh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental cash flow information related to the lease liabilities are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z0kfs87sm8r9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Operating Lease Minimum payments)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zRZKLcftBZk5" style="display: none">Schedule of lease liabilities maturities</span></td><td> </td> <td colspan="2" id="xdx_49A_20230930_ztDKf7vAyQge" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Year Ending June 30:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzfu0_zZw8dvPnCr0h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 84%">2024 (remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">59,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zlqz6kY1OaJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_z2Ty1Hrcvfgf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zJCNlvVJCK3f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest/present value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LeaseCostTableTextBlock_zG9PmHD9XCw" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Lease Cost)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zLsBuNLVlHM2" style="display: none">Schedule of lease expense</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; width: 68%; text-align: left">Operating lease (included in general and administrative in the Company’s consolidated statement of operations)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseCost_pp0p0_c20230701__20230930_z5Z6Dspegv2d" style="width: 13%; text-align: right" title="Operating lease cost">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseCost_pp0p0_c20220701__20220930_zSJaDIryQItg" style="width: 13%; text-align: right" title="Operating lease cost">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeasePaymentsUse_pp0p0_c20230701__20230930_ztwJoNuVNRki" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">17,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePaymentsUse_pp0p0_c20220701__20220930_zKxCov15cJef" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">19,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zQdKkV78smFi" title="Weighted average remaining lease term - operating leases (in years)">1.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220930_zcQfG5h9kX55" title="Weighted average remaining lease term - operating leases (in years)">2.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230930_zBWVs8jATejb" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220930_zCEioJ51cHSf" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left">The supplemental balance sheet information related to leases for the period is as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Long-term right-of-use assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230930_zN0kBp4VWf8j" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">95,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220930_zvCDpjfTJnqj" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">163,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Short-term operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230930_zMgXJ4qVYDKh" style="text-align: right" title="Short-term operating lease liabilities">68,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220930_z8FDKX9lxsGa" style="text-align: right" title="Short-term operating lease liabilities">63,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230930_zt7Sw9yKfqwe" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">34,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220930_zvl7xlSAJBO6" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">110,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20230930_zy9FbkYJ58ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">102,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20220930_zXOZfsuy7SSe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">173,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 19000 19000 17000 19000 P1Y3M18D P2Y3M18D 0.04 0.04 95000 163000 68000 63000 34000 110000 102000 173000 <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z0kfs87sm8r9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Operating Lease Minimum payments)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B3_zRZKLcftBZk5" style="display: none">Schedule of lease liabilities maturities</span></td><td> </td> <td colspan="2" id="xdx_49A_20230930_ztDKf7vAyQge" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Year Ending June 30:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzfu0_zZw8dvPnCr0h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 84%">2024 (remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">59,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zlqz6kY1OaJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_z2Ty1Hrcvfgf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zJCNlvVJCK3f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest/present value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 59000 47000 106000 4000 102000 <p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWAE5Bv5juOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 – <span id="xdx_829_zXr7PvYwSVkg">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued Payroll and Payroll Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In prior periods, the Company accrued salaries and estimated payroll taxes due to a former officer of the Company. As a June 30, 2023, total accrued payroll and payroll taxes-related parties amounted $<span id="xdx_901_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20230630_zEJnGXvTLuef" title="Employee-related liabilities">280,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2023, the Company accrued the payroll of an officer of the Company amounting to $<span id="xdx_902_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_c20230101__20230930_zA4W7Tes8Axh" title="Accrued payroll">46,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, total accrued payroll and payroll taxes-related parties amounted to $<span id="xdx_909_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20230930_zjkGyDHBblmj" title="Employee-related liabilities">326,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> 280000 46000 326000 <p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zNELNACeF6B5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 – <span id="xdx_822_zIUoaO000lu7">Notes Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company received a loan of $<span id="xdx_90D_eus-gaap--ProceedsFromLoans_pp0p0_c20200701__20200731__us-gaap--LongtermDebtTypeAxis__custom--EIDLLoanMember_zAyLzAms8rMb">150,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200731__us-gaap--LongtermDebtTypeAxis__custom--EIDLLoanMember_zZAKELOTox9k">3.75</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum and secured by all tangible and intangible property of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the SBA EIDL loan agreement, the Company is required to make monthly installment payments of approximately $700 starting in July 2021. However, the Company was not able to pay the required monthly installment due from July 2021 to April 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, the Company was able to cure the payment delay with the SBA and started paying the monthly installment due of approximately $700. As part of the agreement, all payments will be first applied to accrued interest until the Company becomes current with the interest due. At September 30, 2023 and September 30, 2022 approximately $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230930__us-gaap--LongtermDebtTypeAxis__custom--EIDLLoanMember_zzAJTs5iXLfk"><span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220930__us-gaap--LongtermDebtTypeAxis__custom--EIDLLoanMember_zcq1LDZM6DUh">13,000</span></span> of accrued interest is included in accounts payable and accrued expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023 and June 30, 2023, the outstanding loan balance amounted to $<span id="xdx_90A_eus-gaap--NotesPayable_iI_pp0p0_c20230630_z9ttaNiGQbQl">150,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 150000 0.0375 13000 13000 150000 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zU16FluH2Irf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - <span id="xdx_82A_zlzc5XWPyveb">Stockholders' Equity</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company's warrant activity and related information for the three months ended on September 30, 2023 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zEXpEAVeeYn2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_z0SWue080x8a" style="display: none">Schedule of warrant activity</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Warrants</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life <br/> (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3G1NCrOeESl" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">53,657,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztcH4zB3Ovn9" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.09</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9Nh2Mw0FEZ9" title="Weighted average remaining contractual life">1.82</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNyMInUaQS0l" style="text-align: right" title="Warrants granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPX0OTFbRE2" style="text-align: right" title="Weighted average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSCQnLzstn4b" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziou13leRjcf" style="text-align: right" title="Weighted average exercise price, exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9TGaxIgE3sl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDCRqNZPDIwc" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding at September 30, 2023 vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zh5WKy4M8pl5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants vested and exercisable">53,927,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvYHF9VXRNxg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, vested and exercisable">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcaEtAi1JmQ8" title="Weighted average remaining contractual life, exercisable and vested">1.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no intrinsic value of the outstanding warrants as of September 30, 2023, as the exercise price of these warrants were greater than the market price. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2023.</p> <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zY0yLbGroBke" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B5_zEUWkXcESe28" style="display: none"> Schedule of warrants outstanding and exercisable</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td> </td> <td> </td> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercisable</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.05</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="width: 13%; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,126,518</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zDv6ogSgJQA7" title="Weighted average remaining life warrants outstanding">3.04</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="width: 13%; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,126,518</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zsUO1tTveqO8" title="Weighted average remaining life warrants exercisable">3.04</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,841,323</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zITgXOJDo4ie" title="Weighted average remaining life warrants outstanding">2.76</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,841,323</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_znCd11J9L3j4" title="Weighted average remaining life warrants exercisable">2.76</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,959,993</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zfdveRopLUeg" title="Weighted average remaining life warrants outstanding">0.24</span></span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td> </td> <td> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,959,993</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zNRp42gs9ema" title="Weighted average remaining life warrants exercisable">0.24</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,927,834</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,927,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zEXpEAVeeYn2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrant activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_z0SWue080x8a" style="display: none">Schedule of warrant activity</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Warrants</b></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life <br/> (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3G1NCrOeESl" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">53,657,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztcH4zB3Ovn9" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.09</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9Nh2Mw0FEZ9" title="Weighted average remaining contractual life">1.82</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNyMInUaQS0l" style="text-align: right" title="Warrants granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPX0OTFbRE2" style="text-align: right" title="Weighted average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSCQnLzstn4b" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziou13leRjcf" style="text-align: right" title="Weighted average exercise price, exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9TGaxIgE3sl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_d0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDCRqNZPDIwc" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding at September 30, 2023 vested and exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zh5WKy4M8pl5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants vested and exercisable">53,927,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvYHF9VXRNxg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, vested and exercisable">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcaEtAi1JmQ8" title="Weighted average remaining contractual life, exercisable and vested">1.57</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 53657234 0.09 P1Y9M25D 0 0 0 0 0 0 53927834 0.09 P1Y6M25D <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zY0yLbGroBke" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrants by exercise price)"> <tr style="vertical-align: bottom"> <td> </td> <td><span id="xdx_8B5_zEUWkXcESe28" style="display: none"> Schedule of warrants outstanding and exercisable</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="8" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td> </td> <td> </td> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercisable</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td> </td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.05</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="width: 13%; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,126,518</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zDv6ogSgJQA7" title="Weighted average remaining life warrants outstanding">3.04</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="width: 13%; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,126,518</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zsUO1tTveqO8" title="Weighted average remaining life warrants exercisable">3.04</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,841,323</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zITgXOJDo4ie" title="Weighted average remaining life warrants outstanding">2.76</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</span></td> <td> </td> <td> </td> <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,841,323</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_znCd11J9L3j4" title="Weighted average remaining life warrants exercisable">2.76</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,959,993</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zfdveRopLUeg" title="Weighted average remaining life warrants outstanding">0.24</span></span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</span></td> <td> </td> <td> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,959,993</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice3Member_zNRp42gs9ema" title="Weighted average remaining life warrants exercisable">0.24</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,927,834</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20230930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,927,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> 11126518 P3Y14D 11126518 P3Y14D 23841323 P2Y9M3D 23841323 P2Y9M3D 18959993 P0Y2M26D 18959993 P0Y2M26D 53927834 53927834 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zWO3WHfU42uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8 - <span id="xdx_828_zj1chxP9Hrb6">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Royalty Agreements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2008, the Company entered into Patent Assignment Agreements with two parties, our President and Technology Development Supervisor, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and the Technology Development Supervisor have been assigned to the Subsidiary. In exchange, the Subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and Technology Development Supervisor for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by Cavitation Technologies on May 13, 2010 from its subsidiary. The Company's President and Technology Development Supervisor both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with our former Director of Chemical and Analytical Department (the “Inventor”) to receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of September 30, 2023 no patents have been granted in which this person is the legally named inventor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

>F\*8H M*Q]*/8[\P?;4/8IQ?9[<[A_&^T.Z;V,;=-;G NTB_$C@9J9:CIMT>]K^#GD= MU^^->/P1\T[8A=0\+N>DFO9/CWNQ#)L7;\JPC,^,I]4^/"[ILD++ O1];FAS MJU_80/OK[.I?4$L#!!0 ( #%I85>UZ00_P@( ,<& 9 >&PO=V]R M:W-H965TW.3:6#AV9CN4_O<[.VDH6EJ)E_CK[O>1G"_CC=)/)D>T\%((:29! M;FUY&88FS;%@IJ]*E'2R4KI@EI9Z'9I2(\M\4B'".(HNPH)Q&4S'?F^AIV-5 M6<$E+C28JBB8WLY1J,TD& 2[C7N^SJW;"*?CDJWQ >V/-V9N#<[)4ZLDM;K-)$#E!*#"U#H'1\(S7*(0#(AE_ M&\R@I72)^_,=^A?OG;PLF<%K)7[QS.:38!1 ABM6"7NO-E^Q\7/N\%(EC'_" MIHY-*#BMC%5%DTP*"B[KD;TT[V$O810=2(B;A-CKKHF\RAMFV72LU0:TBR8T M-_%6?3:)X])]E >KZ913GIW>HV 6,U@P;;?PJ)DTS+\O,PXMX;NH,&VPYC56 M? K@3LE;6[@L\PP>YL?DJY67+P3-X^/ CY@V8$EK-O%XR;O- MPN_9TEA-JS]=OFO883>LNS>7IF0I3@*Z& ;U,P;3TY/!171U1/2P%3T\AO[. M+W04JUOI=V41SN'T9!0/!E=PY"7-TE17_FBKE1# Y.O\D;V@@5L)I>9*0XDT M9.8,;(YPK8J2R2U=P3K?,,$T1]-S &@L+SQCV4!9#Y55"%8! ]=Y4(-:K7CJ MQWW,/LP,Q7RK)+:50J3*,M'2E7MRWW!\U+777DE>20^P0E722?D \2@ZBZ(( M;BK-Y=I3VEPC0E'7.+H:!ZI0B\629+7DO2[';F]'30:8/&"G4> 9%:D87G@1 MY)'B.LBZG?8..H7_G'J:)*YYNLHUW&LN]!W6OH4:2%U^W6?:W;9+S^KF]!I> MM_@[IM>__? P K @ !D !X;"]W;W)K&ULA59M;^(X$/[.KQAE]U9W4D5"Z)NZ@$3;/6U7VQ/: MWLN'TWUPD@%\]4O6=DKY]S?C0 I:X"1$8GOFF>>9\=@9K:Q[]DO$ *]:&3]. MEB'4-VGJRR5JX?NV1D,K<^NT"#1TB]37#D45G;1*\RR[3+60)IF,XMS,34:V M"4H:G#GPC=;"K6]1V=4X&23;B6]RL0P\D4Y&M5C@$X8_ZIFC4=JA5%*C\=(: M<#@?)]/!S>TYVT>#/R6N_,X[L)+"VF<>/%3C)&-"J+ ,C"#H\8)WJ!0#$8WO M&\RD"\F.N^];]%^C=M)2"(]W5OTEJ[ <)]<)5#@7C0K?[.HS;O1<,%YIE8__ ML&IM\ZL$RL8'JS?.Q$!+TS[%ZR8/.P[7V1&'?..01]YMH,CR7@0Q&3F[ L?6 MA,8O46KT)G+2<%&>@J-527YA\IL-Z&$FUJ)0.$H#0?)"6F[<;UOW_(C[$!ZM M"4L/GTR%U;Y_2E0Z/OF6SVU^$O )ZSX,LS/(LWQX F_8Z1M&O.$1O'LL MQ+ M7RKK&X?P][3PP=%>^.>0V!;K_# 6]\>-KT6)XX0:P*-[P63RX=W@,OMX@NEY MQ_3\%/K_5^*D^V%RC F7\.'==3X8?(2]$/!@>E\:M>9,4[[#$N'.ZEJ8-35; MB=0K%0A05ABPE\9X>=/#_=??P'AO?1!F!*A=G;AA.[#[P3%JVTHZ:'>\+,O!#W,8(W" M^3,H^ '2$";Z ()^X 3I(W;#_M4%_-2KR4$8TVCZK\!C216OH%B#4 HH[$(R M+J\1S'9(1,@OK!EG)PE]F#7.-\*$7K!Q@0)KO[5B\6^LQ<(ATE$5]O-(8AQ^ M;R2S(! MGA$T]PME71I*A%+LQ(KY&<%%381>)9TW2%;OK[(,R- %:18]:6!; ML4$?/ML54HKV0ZZ$!V,I-RR-8A)T7.]X'(I?-0BQK!TZNTYK)U7LPSX5%1Y% M7!K^&&\;B],=%S=ZZ'14Y+228V MQ=A)/U>Z2^=*TJ@@;=+QCJEK);'BE]*BEAMQ1K(:$'('YTACL9MK/TIVM>'SJITYP;1Z!;QGB3QC-=> M)MUL=Q5/VQOHS;R]QQ^%6U 90>&<7#/JS 1<>S>V@V#K>!\5-M#M%E^7]#F! MC@UH?6[IF-H,.$#W@3+Y#U!+ P04 " Q:6%7?:?I6+\# _"0 &0 M 'AL+W=O.1I\E6 MJD>=(QIX*@NAIWYN3'45!#K-L62Z*RL4)%E)53)#2[4.=*609SB:Q-P07.%>BZ+)EZOL%";J=^Y.\W[ODZ-W8CF$TJML8%FC^J MN:)5T*)DO$2AN12@<#7UKZ.KFY[5=PI_T828.+WD%KPD,_KY>:J.H$OXY%V,#T3L/86_'E:Y8BE.?RE^CVJ _ M>_LF&H0?+A#LM01[E]#_]SE<1#G/\8LT"$-X#^=\-)OPP)1BPFBXWE]/D"LP M.<*M+"LFGM]IV#8ZS46RIDQDGL*"&-9L[4Y H1RJ8RT%8&D)2. MUF"Y1-6>+W -3)-904^$OO(6]/)D=8&6PJE3KV7ZX"X<9N_A>H.*'A"X>T*5 M'#>3SJ#_K 3)SWX#L)N.(:H.XJ]GZT7 M8OSVS2B.H@^GH[=W=DFCXNJ"_(35F;QL4%L*I /8N&-+2@LQ'L?#SNB8<7\( MO^>HD!*F04@Z#Z,X/9TI;%A1X_XTY<&GM]UGDBQ(_-)_QTJL%>X36[G$-E@: MH4786L]K:@H&[=$SX/O"/!G;VH$O MM>-YC[9]6@^O2KSY/O6+G-'5AE_Y"N'[OY I_0-<$GJN1A*Z_S3T(8HZ43SH M]*,1)-UP5T')Z;;GRHI*8-2+.@F58MP=#N#[+ M;>^H=H^FYQ[0X*BIE:C6KG5K*HA:F*:_M;OMW\%UTQ0/ZLVOQ6>FUG09H, 5 MF8;=8=\'U;3K9F%DY5KD4AIJN&Z:TQ\.*JM \I6D-W2WL [:?Z;9?U!+ P04 M " Q:6%7P)@XBJT$ *"P &0 'AL+W=O,E4;I=!ZEQQ-1[;*,5, MV)$N,*>3G3:9<+0TR=@6!D7LC3(U#B>3#^-,R#Q8+?S>O5DM=.F4S/'>@"VS M3)CZ&I6NEL$T.&P\R"1UO#%>+0J1X".ZWXM[0ZMQAQ++#',K=0X&=\M@/;VZ MON#[_L(?$BO;^PWLR5;KS[RXC9?!A FAPL@Q@J"O/6Y0*08B&L\M9M ]R8;] MWP?TG[WOY,M66-QH]:>,7;H,Y@'$N!.E<@^Z^@5;?RX9+]+*^D^HFKN780!1 M:9W.6F-BD,F\^18OK0X]@_GD"P9A:Q!ZWLU#GN6-<&*U,+H"P[<)C7]X5[TU MD9,Y!^71&3J59.=6&YUETI'*SH+(8]CHW,D\P3R2:!=C1T_PQ7'4PETW<.$7 MX&9P1P"IA9_R&./7]F.BUO$+#_RNP[. CUB,8#890C@)9V?P9IV_,X\W^S_^ MPHVTD=*V- A_K;?6&4J:OT^IT#QRM"U4*Z&=6(0FTN_Y?!KJ6J8.%H/UM;*)&?C/DPE70JNTE (X^BI(>C2P#T1 ME#%?92Y/&*6Y5CJIX0;WU%\*C_)8%N2$M-H,H4KI/8C0..I/5*U[&6'C2(8N MU;$E*GNM]A@/Z)RIIG5L=%SG(I,11&(OG?#MHS":3"UZ"_8CAFWM+5Z3XIW_ M) :IV"-L$:DM>?<)C10AV\%CN24T20UR!+)1-\Z3 X@[FC&* M0M$_-:@$RX3/I6P$P&Q+TO*5U]8C>$HI\QJ?VOASW"RY2]:TH>H!"55FC>J; M8U@ZYIR.M+XC,:8SSKWI!'9&9R )S?9$?3KFX[?V:S-JL-64EY6@?Q(?:FG M<-_W^AJ,D ZZ4%!@&F=<*EP3=<5)>!3J=:T*RL2L4-H[=(Q34Z:,PN,!0=]($L&1=TZ$UBYN,L G8QL3ZNDH*"F:8M])8QW4* R7?Y5**I!^OVIQ M[-N0=L"%[V(]VX,?E"76;RA,!"M,+<7+V1P/O2RS-UX,3GC1-IHC*TLS!Y?1 MOUF0$[[(CX7CG1O!VO([7>9T_ZB0Z];6]GI28@0WN+XFT@+5@*4TDN>\&L&I M/[AQ;SZA+$G\%&8AXH@VHTJWVPUZZV:^.5YOIL0[81*96WI^1Z:3T8^705.! MAX73A9]VJ%!I=O(_4QI6T? %.M]I^FMK%_Q -_ZN_@%02P,$% @ ,6EA M5UW5D!F6$0 $#( !D !X;"]W;W)K&ULG5OK M<]LVMO_.OP+C=KKQC"Q+Y^\\ +_<6??9;Y0*XF%K:O_J9!-"\\/YN2\W:BO] MU#:JAB-4[*B15MSOIC-KLZW4MKD>O[#F_D"%] ;_]!JYWO7 D596OL9?[RO7IW,D"-E5!F0A(3_[M6-,@8I M 1]_1*(G^9NXL'^=J+\CX4&8I?3JQII_ZBIL7IT\/Q&56LG6A(]V]U<5!;I$ M>J4UGOX5N_CN[$24K0]V&Q<#!UM=\__R(2KBSRQ8Q 6DB'/^$''YHPSR]4MG M=\+AVT -+TA46@W,Z1JM@!>D>%[&[[[A[RX.?/="_&+KL/'B M;5VI:KC^'&3(@BR2(&\61PG>J68J+F83L9@M+H[0N\B*N2!Z%W]",1-Q8VL/ MPE:=GFZ=\JH.? .4]4[7LBZU-.(.;BIPW.#%OZ^7/CCPO/^,:8@9>#K. (;C M#[Z1I7IUTN"WW+TZ>?W=-_.KV8LCXCW-XCT]1OWU&^FU1[[[93,.).C MM,5O&P4Q6-IM(^L]^E%IP?2U5Q5>1>W"CU529.$[16[DO1)+I6H!GVFD@_=T M3>1-V>,3U2 UV?EMXS30;0QZ[G??/%\L9B]^NKZ^IH)W@D1/H/D8%->HE4_&>;68;7<>PW,H:D@L^ MGHB=8C^*;%3$AZQ^!Y1E-E$0#0J 1[4JE?<(A$_HKB<7 H(ULFN .S".PWL] M J<%\BC%2FHGFI[S3\6'!CR3:,!MR!B>Q$%FP\8I);:,AFS)._3=[1(LD0!- M@,M'%5;@?)C)D@83O;"1 <3=0Y@4ZJ&!K(?6B!]9:5\"UWLE'7X#^?A;6ZM$ M_^E4_,NVPF]L:] /9<5&!G^0;84!\-5H[9L;0@=>^KVMR?\+"@CD(M$:7836 MQY?8^G#E%$1(ME4,QQO&C[_@^W5+AFBL@X"H-Z(KS$M )1O-'E!F_"ZL;(Z"SHM";5,6 8Z;WJ.17\"(:^A@^-EDMM.F@% M9K>:0[B(-HAA#LG#>0JU9>M!%QY YAJQ:64XP&(6^O/"3D35$FY\+?:SMT[Z MCH_. L"#X 48%82QGASQ6[&XG$]FLYF83^;/9G1U'=/(8S 9$D2G+:7?),GE M%A,FTYP_94J_]=Y'B)'&6R$#6H#RF),:M"0K<'+0/WAWI98!57L.#HPX'O9) M&2BY%2M(- #3A(F8[LA.%O/OO:[ZE*BH)\7*1@=I*$(!"Z' J"U:N744E!0E MO@7/Z+ZST\842Z!V+[612Z-2@*W:T (-X,TN W0N;$??KE98SH+PK /?RP+ MW!;#OJ(A#:I=%KIC45=XSD7?;#G&2 1,$2/U+5T"/0PN!D 5?@ MQSHFCT+058:@JZ,0](D#ZBVDU"V&[Q@*':4PCD*/R9+3,IYD5 B,[E\I-CE] M85V"?DO9:[R,'*DW4]4(16&J8'S?#&A$^5D)E=E$UT<_AE!"%1?D!'*U GR) MP(8)#@,^.N40W7I8!M ":1X0@9Q[1=X!')-#CRX0T=U&<*I _<2J],OO.W#C MNN7G6&M LO1]7.,UI"W(A+::#GK)GNS :.M9;1J<3SM2$JC+[+&' !L4*_V@ MJBC !!7MR-M7HH%" 02$'T,=J)4B@ SRH2_WO30MU7"M S%M^1G\FC0.*44Z M0!$B'[,!N N_H\$R7$<5Z&>ZQ$^ )I 0UB@0(&J+28&#,!5C)85?I<&,+EI*NLJ+-Q;^RYW3N^N[-[DY&7W_QE;D-/3]M.SZ[B:ONII=341B MEO1\$R'14^ 6-S1"4<[WE^.R1 ),QS=$"24$.27$P[TZ\T$UD)HK91B7W475N)&(\%$&YK4\A2=RE.B;6?L#>_%3 $J"] MVJ+CR*ZVJZ8"I MMC2:.]F!3WMI*+K0K+]*J'L^@DJ"!:?6/BL-ODA" /M5BR(AN/J-;IK4B.!R M4&"[PHJ!?!.NJAIR2^OZBPL14(>J]X3C"&T4UE;URO3*G*%^S@C(@)='=R5$;*K[K$&B&/B M"31105168>T>./BLF0CLK!A#8JNP99&PT,E9@8-[^$)?'K2RQDQ%]1C:V]&( M)X G^L 8X]NE!PKPOMD##B+@^S@DB>T%^[,&/G-;DF N3N6PZ8*EX"1,LU)C M9* 0^RJ9 GNWJ8AF!!MTI,43?';:S0\.R8T $"GW77NL2P&-U':K2U@-\ [K MI\7;H]J$@--J%P7K56>(,@I= .25D@_21&">)[JO8IG@L0QR)8_ M6W"I&U$J?Y):?*#3&(GY$2U&PX&--5575\-45C=\7G%;GVIJRG \ M99GRB* 8FS?6U7"X-1E*GG5/4A[THQV R+>"!Q-'$/7[C*C?'T747R%"GOQ, MH7$+W-YM0(HQ-#U*91Q-QTCWD33'$0Y[VF[?A_P&[ &I%E84JWN7B]1< MX^$$JV34T*9%KX#7IN(-W8;+@?])'P?D! B=D8,=="CH$EC>5AHG)U5,9,6. MMB.1#$;46N4UR"6F^( A2LZ4"I/4JOT8>8M?SK*EJ1?SU75?) NE[P[(@R,Q M]@5W4>P9<43"O9$MPYRK]C;%P,Q8F,2*).W*T4X7 MF+^Q/I;@7[BHD@Z]OL<8Y)LPNKE5C^QY+89#R2P.Z;WGQ#W\X*,E7.7C>9/4 M9,>6C)8FO*0-)C0CSF5)IHR-0TB8L *I.QLJ$&]%88LOA9U$!(>T'ZV[(^#K M-CL&+C M[LJ-JEKN]/!1=@[F:RQ+#S)T#B1*5?,7D'87ES2_+_Z9PNKR8G)U M^6RRN'C:OSR2F>>S[B#)[&ANIOT?A&UB8O1$R%$"XVEY2%7<2+\19[1?P;4A M^)^.N&[K_B03-^!UH,0T+3"/Q^T[+S;*1&S6?GP!/=5;Y>-^:NSC8P7X3F'' M;\2/_'' Y[0)<6,=%I>#:=6[']_G<17T'.E5H[>:9ZEM@S[X;335- W"O+B5 M>TKXM&V/8T^,U31LC38NPLX**,,K' ;$9BE6[(L%>(:XA'^OTC2AU!G MM <5@:\XL L-$?G]Q5%GZ9TZFA]UEG=8#?^#:LA?N. YU!@?)S3N-./4!&E*_/1MD/O)<8"%8[@R58NI!QFT(#CTC$)5:H4[FR/LRU$!@/.BMU$H0V]X MT'N+R[RERA,PWBS-O4U_7KA488>(B ,VZF^D0V5PS\^;I 9V'.Z0229#ME;'&!OR!-R MX $YC'3CWY]\*43BGIOG>(R$)9MT%;>N(7OW7K)+C"7>H\2Q!MH(3.J<72+" M<:/1>PF*5LGLM4M,S7$.P[NMQ@CLX9/Q1CE_I(^+ _IXS&=;=TQ,X.--W*P" M[H!N8/9KF\H_DAOMP&5M)-(?<\4)Y3 0#G,M/M2'*IJ1]AFI%D25RPQ,8[3E MA!>(+?",(2+/[9I>%I Q"Z0MM\G@+KSIK.'A6[H.\@%G"PU4[P\, ER1I#X^ M,5.U:5ROL7P!'9Z1Q6J)^\Q'IZ'S10?ZBZ]L5V$J'QPE=;:&ZY+W-4;A_RC) M0YM7Q[^#'1499S&;7[%ANM.;8_FAB/M6O0-V@[VKN$EX??=)_&JG1/9L#B:_ M@4(9(!FG"J#CLT$R O,/'^,)ILS%^RY=]/+1IR*2[F]>?4K?&\].+1[,P,B$ M_J0Z,];2:0KR"-Q6^6+DE(^.EX2$S=O;W[.6;&?7(:O(\$XDP_[AKW] M0#+DZ0A5(TY6- 54FN*9\%]S$<8-?.K&H=HV /LI,](I,\Q7"/Q$9C".QI\I%ZC-RI@WL >,U3Z-(V-WP28*/BEH_2+(XE0WBT[U2D^3:V M('3<8S@MP9$C'^"D8T9JU^V?\FZ[D7S1P!IG[_/F'Y\)0:T[I!BWCCKU M4EF* YDB;4?CWM'PL TAS@KS)$ 890#'43,XZ3"(&O;R(NZ48 #TC89BOC>"(>G:W)O;'6)G"] 4?1N'\G;MNET64*P6Y''M<. M3\,6^7CJ#9[=\O1' I7F>@EW-&.>BS:@?# \A1&'"UF+R2Z/CQG&(0T2[0[= MY ,DQ=@1KW&X/.\=TD<]T9\BT$F!.O!Y_7PW_[G#-1_R[U[GOY7X1:*:/=1$ M*U@ZFSZ[/!&.__R ?P3;T)%_*#2#W=+E1D%P.7P!GN,IV_0#/Y#_".3U_P%0 M2P,$% @ ,6EA5Y;OWVM_ @ CP4 !D !X;"]W;W)K&ULC5113]LP$'[G5UA&0IM4D31I 4$;J65#8Q*B(MMXF/;@)I?$ MPK$SVZ%LOWYG)PV=U'6\)+[SW7????9YME'ZR50 EKS40IHYK:QM+H/ 9!74 MS)RJ!B3N%$K7S**IR\ T&ECNDVH11&%X%M2,2YK,O&^EDYEJK> 25IJ8MJZ9 M_K4$H39S.J9;QP,O*^L<03)K6 DIV*_-2J,5#"@YKT$:KB314,SI8GRYG+AX M'_"-P\;LK(GK9*W4DS-N\SD-'2$0D%F'P/#W#-<@A -"&C][3#J4=(F[ZRWZ MC>\=>UDS ]=*//+<5G-Z04D.!6N%?5";3]#W,W5XF1+&?\FFCPTIR5IC5=TG M(X.:R^[/7GH=WI(0]0F1Y]T5\BP_,,N2F58;HETTHKF%;]5G(SDNW:&D5N,N MQSR;W.N22?Z;=1+)G*3=Z1!5D)27DA<\8]*219:I5EHN2[)2@F<<#'GWA:T% MF/>SP"(3AQ=D?=5E5S7Z1]68W"EI*T,^RASRO_,#[&!H(]JVL8P. J;0G)(X M')$HC.(#>/$@2^SQXC?(,B+72AIL.G]5::7!@+2= Z6ZX9+)C#-!4G0"WEIK MR/?%VEB-]^['/H4Z I/]!-PL7IJ&93"GC:NEGX$F)\?CL_#J0'N3H;W)(?0D MQ=G.6P&..IXNS[EHW7004S&LMH_N0<#]=/]3Y0@/#:5:@QY.CGQN)0S6T7WC M]#7DY/@B&H^OR'@43<-1&(9'CTQKYC2>QJ.SZ?DHBB>[RWT2!3M#4H,N_5-@ MB+_6W;P,WN&U671#]AK>/55W3)<<>0DH,#4\/9]2HKOQ[PRK&C]R:V5Q@/VR MPA<3M O _4(INS5<@>$-3OX 4$L#!!0 ( #%I85?1I%NUO0, #\) 9 M >&PO=V]R:W-H965T%1$-U5%UP&74 _( M,'Y'TC@=]N -NU"'#F_X>Z&>BM #9*6:6-/;\'NFA+(@ZQJ M*E[>OKE.D\FM1E2A)6<%-8B@#?YAW1O+5'I'N'])_B#)S;LXCKM!\ 7!%(+Z MYH2GIL$#U26I*2L(+A):R48838[I60(5LFY4Y\4'P1E=,=G$;N :P@-G@$9A*ET(3: M18Z-&5/Z28K-E8M!V4"OY/JJP:BHUF"L'C>CO1[CH1-D64IEO,4O7']1I VWWU$2IWN.$^>*]-3EJ*O+T?^LRV.G*':CW/!4 MF?8B_VZ9GG9W*,'@/[Q6MNM:6?YN!&#A3GV/L^6;D8O#3;TAE6O2MIA&_E[C MD1'))D[+?MVZU^SJX\X_BX;C_M/A,U88)C136 M:!H/)I@7Y9]K/S&R=D_D2AI\<-VPQ"\<4/8 [J^E-/N)==!],RU^ E!+ P04 M " Q:6%7=X(V4"<# ]" &0 'AL+W=OX1O6ENA#ZY')LNW< 0PAP391"H7F[P%>:Y =(TOK>8;I?2!/;W M!_1_;>VZE@V5^(KG5RQ5V=*=N9#BEM:YNN3[-]C68PDF/)?V%_:-[WCN0E)+ MQ8LV6#,H6-FL]+9]#KV 6?! &D#B.7=)+(L_Z&*KA:"[T$8;XUF-K94&ZW) ML=(T9:V$OF4Z3JW6BB?7&<]3%/(IG'^OF?H!SS[338[R^<)7.H5Q]),6[JR! M(P_ 1?"!ERJ3<%ZFF/X:[VMJ'3]RX'=&!@'76(T@"CP@ 8D&\**NWLCB10_@ MM17^?[J12FA)?#M68P,Q/@YA7I,36=$$EZY^#R2*&W173QZ%D^#E ,%Q1W \ MA+Y:Z]H-"OZ!P M?HLB81+A0K $[QR<3[62BI8I*W= %;RK2^QZ!G'D3>*I1Z(Q/(9@%,PA',V( M\]IDP12>/)J1,'QY?W4.R88\*B8&[N^QTDI26&Q0W%&[06DH:!_ )IW1O6$\ M)U-OUF<<3V&@N7'7W/AOFRN!]WG^2N58PPB:#_##OC>=^S%0'\ MMG$.LKFW=IV%C[5MQR6:X6$R/'CC-(K3]-<9U67!>[9%>/8?4B&?P]"E8SL8 MP0NSQ!"&7D@F7AS.(!H%;7^C^V;'-IU$WFP<>I$6"AE-)W#,:.%# N',F\=S M;SZ/])DTN+^;G9ZR>MMCPO)[G_0"Q#-8/ M5.Q8*2''K0X-1E.M(-$,J^:@>&4'Q(8K/6[L-M/S'85QT/=;SM7A8!)T_QA6 M/P%02P,$% @ ,6EA5]PIM5CG @ T@D !D !X;"]W;W)K&ULS59=;YLP%/TK%I.F3=H*@7RI2Y#2--,ZK6K4:.M#M0<' M+F 5V]0V2;M?/]L0%MH$;5(>EH=@FWN.[SF^QIYLN7B0&8!"3S1GDKBP$X-B":.[ZGC=T*2;,"2=V;"G""2]53A@L M!9(EI5@\7T#.MU.GY^P&;DF:*3/@AI,"I[ "];U8"MUS&Y:84&"2<(8$)%-G MUCN?CTV\#?A!8"OWVL@H67/^8#I7\=3Q3$*00Z0, ]:/#H]0P,7\1S:?_1MH[U M'!254G%:@W4&E+#JB9]J'_8 FN!; M)$RT9C,-ZXU%:S6$F55<*:'?$HU3X8U(,2._<.4IB]&J6D[$$[0B*2,)B3!3 M:!9%O&2*L!0M>4XB A*]NP2%22[?HX](9EB G+A*YV28W:B>_Z*:WS\R?X"N M.5.91 L60WP /^_&]_P. E>;T3CB[QRY\#L95U"7K'^%;/)9$/:.;PJ[0_370-8B?AXSNY#%?@W-9X BFCM[N$L0& MG/#MF][0^W1(Y(G(6I+[C>2^90^.2)[I.HM)7IH-CE80E8(H4V^+IR@O]2*C M1'"*YIP6I:H*5Q?K @NFJU.B)0BT,M6([K]I8G2E@,J#AO5/:=B)R%JK# M!ITUTC+L^$ZL2 :6Q'S=-Z$W<3?[(EY']/R!IW]-7"N_89/?L#._.RR$^8AT M56\GP[\NQHG(6F)'C=C1?U&]HU,:=B*REF'CQK#Q*:IW_*HV!\%P,/*#_HLB M_HO *D]W[]BD(%)[FY#('G35"=J,-A>6F3VGW3_AU6WG&HN4,(ER2#34.QOI MZ45U@Z@ZBA?V$%YSI8]TV\STI0N$"=#O$\[5KF,F:*YQX6]02P,$% @ M,6EA5\K YX!Y! OQD !D !X;"]W;W)K&UL MM5E=;]LV%/TKA#9L+;!&7[8<9[:!Q%*Q#$MKQ&OW4/2!D:YM(A+IDK3=%/WQ M(R59EFQ%BP?VQ98HGG-YSZ4N><71CO%'L0*0Z&N64C&V5E*NKVQ;Q"O(L+A@ M:Z#JR8+Q#$MURY>V6'/ 20[*4MMSG,#.,*'69)2WS?ADQ#8R)11F'(E-EF'^ M= ,IVXTMU]HWW)/E2NH&>S):XR7,07Y8S[BZLRN6A&1 !6$4<5B,K6OW*G(# M#X/*!WJ:[Z8I2+_1;NRKV.A M>",DRTJP&D%&:/&/OY9"U "*IQW@E0#O&-![!N"7 /\8$#P#Z)6 WDLM]$M M[KI=^)X+%V*))R/.=HCKWHI-7^3JYVBE%Z%ZHLPE5T^)PLG)>[[$E'S#1=1H M@N;%C$%L@>9D2'MQ;KQ.QCFL+Y#O_(8\Q_-;!C1].=QK\Z<;_N>&=EJ/7@[W.L3PJYGBYWS^ M,WPSSI)-+-$M+=*3GC"?_E*=T*V$3'QN"WC!V&MGU#GP2JQQ#&-+)3D!? O6 MY)>?W,#YO4ULDV2A2;+($%DC++TJ++TN]LD[M9BD3(@V^0MDD"/UBK&=>'W7 M<9R1O:T+>]IMX)_T"CN'<:YBAL@:BO4KQ?J=BLTEBQ]7+$V BU_UHJ*RF6R3 MKZ#IUW1QW8%SJE__1+\WPZ!%P=-^0W=XTBUJH7,=/ZAW;/@=5'X'G7Y/L5BU MN1F@">/HTQUD#\ _H^_[ M781 ,_R$'U*H/]NO+U-&8Z4S+U:8>R(>JUYMVG<.X]PEQB19:)(L,D36B.6P MBN70^,H_-!D6DV2A2;+($%DC+*YSV+L[W1F]\:IP_:JL@>LF5>.U;L +OLM: MWG N].ZPD:FZK9ZK=ZO-_I'-R)3-II*U*LCM5/+O'2O3E?C!^:I[(.>^&4;9 M0J-LD2FV9DB]0T@]XUFKI#05')-LH5&VR!1;,SB'6M+MK(G^1^;R6[*(?YRX MC):([2:#X\3U(XH_]U#]N=WE7PA";5'K>>D>MD W@&Z QJL,\\?ZPVG^10GX MV5G+9/4W-^>'1R3;*%1ML@46S,XAP+:_8\* M^NRL9;)HGI9LS80T/$J"H5&;D2FV0G&[]J%:9:%E?D(@4+[)*C[+5JW5*<1U M_NW]J/W&O9H69PD'FN)HXP[S):$"I;!0E,[%0$T97IP6%#>2K?//X0],JE28 M7ZX )\!U!_5\P9C&ULK5=M;]HP$/XK5C9-K=0U M(01*&2 !R;9.ZE:5=?LP[8-)#HB:V)GM0"OMQ^^S M/=AP\2A7 (H\Q1&30V.E5-(W3>FO(*;RDB? L&?!14P55L72E(D &F2@.#)M MR^J:,0V9,1ID;7=B-."IBD(&=X+(-(ZI>)Y Q#=#HV5L&^[#Y4KI!G,T2.@2 M9J >DCN!-;-D"<(8F PY(P(60V/>/NG(3# U+ M3P@B\)5FH/BWABE$D2;":?PI.(W2I ;NEK?L'[.UXUKF5,*41S_#0*V&1L\@ M 2QH&JE[OOD,Q7HZFL_GDDNB7;4B+L@8@W-"HP@D=I!/@J<).7-!T3"2Y"L5 M@FK7GI/WY&'FDK.WYP-3X40TG>D71B>Y4?N(T1:Y1;,K23P60%"!G];CVS5X M$P4H5;"W*DSL6L)OOKHD;>N"V);=JII//7P&20EO5\#=U\/M"KA7#_^2LF/6 M]\1HER'1SOB<(WQW($(>A#Y)Z#-F!%7EWYRAFS'H5+0>.19^!N9Z5[5:.SH# M]F5"?1@:F.(DB#48HW=O6EWK0Y6&39)Y#9'MZ>N4^CJU^DZS70V"T&!-F0^R M2N!:BA-7.W4.O-6][ARXRVW2IG=HLWW=VK6YIUVGU*Y3JUV1GW[=0CP'\;M* MN5J"4Y5KDLQMDLQKB&S/"]W2"]U:+XR+P,6+@@]X&%2E\$DMQ:E^R,DZN]%D M.8<1W*1-KR&R/86O2H6O3HES\A=/7L;)/>!1S06943R>:W=!+?VIZC=)YC9) MYC5$MN>C7NFC7JV/[F$-+ 6R$#PFVWM4?HW:IO@+4U]"L(_+&05Q1/LMOPG"MT M459&PO=V]R:W-H965TW4=J#]][.=D/(1LG9B>X'8\3GWGG.Y MYO97C#^("$"B)Y)0,; B*=.>;8M9! 2+1%)OV'X_Q0N8 M@+Q+;[A:V25+&!.@(F84<9@/K(M&+^CJ\^; CQA68N,9:253QA[TXBH<6(Y. M"!*82U9$'>91W0-1/31F5$8"7=(0PFV\K124,MRUC*%;2SB!]!QY MSD?D.JY7D<_H]7"W A[4P[]E]%#T+35>613/\'F'TE'-'68)(#9'EWE)QGE) M7LHET/VU@J$K"43\JBI!'J-9'4-?)SV1XAD,+'5?".!+L/P/[QIMYW.5?\\[9VLAD5WAK+]>S1G?/GZ VN;\L=KN4WJZ5?D& M0PA+=#\&,@5>V2>U%&_MDV.2!48WAZ3+#@2V9:WW=+; M[C_HR.Y>O^UVY/Z)1F>_(6MS>ZMR>V/T4,VV,".<0#.649G_?9>[Y91X88:C MG?UAHS?*A[T7FGST'&.^B*E "43<*S\>Y?"%9:@:<*9-J7#*/D9J M@>L#ZOV<,;E>Z #E3.W_!E!+ P04 " Q:6%7#&![Y9\# "X#0 &0 M 'AL+W=OW08D&]KI\9Z6P1E425I.SFW^](*8ILT:H3](LM4G?/W?/P>"+G>RZ^ MR11 D1]Y5LB%DRI5WKBNC%/(J;SB)13X9L-%3A4.Q=:5I0":&*<\

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

&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " Q:6%75@Q15'\! M ##$@ $P @ %KH 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 )0 E /H) ;H@ ! end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 58 141 1 false 21 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://ctinanotech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Sheet http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) Sheet http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Contracts with Desmet Ballestra Group Sheet http://ctinanotech.com/role/ContractsWithDesmetBallestraGroup Contracts with Desmet Ballestra Group Notes 9 false false R10.htm 00000010 - Disclosure - Investment in equity method investment Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestment Investment in equity method investment Notes 10 false false R11.htm 00000011 - Disclosure - Operating Lease Sheet http://ctinanotech.com/role/OperatingLease Operating Lease Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://ctinanotech.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Notes Payable Notes http://ctinanotech.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://ctinanotech.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://ctinanotech.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Operating Lease (Tables) Sheet http://ctinanotech.com/role/OperatingLeaseTables Operating Lease (Tables) Tables http://ctinanotech.com/role/OperatingLease 18 false false R19.htm 00000019 - Disclosure - Stockholders' Equity (Tables) Sheet http://ctinanotech.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://ctinanotech.com/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails Organization and Summary of Significant Accounting Policies (Details) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Contracts with Desmet Ballestra Group (Details Narrative) Sheet http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative Contracts with Desmet Ballestra Group (Details Narrative) Details http://ctinanotech.com/role/ContractsWithDesmetBallestraGroup 22 false false R23.htm 00000023 - Disclosure - Investment in equity method investment (Details Narrative) Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative Investment in equity method investment (Details Narrative) Details http://ctinanotech.com/role/InvestmentInEquityMethodInvestment 23 false false R24.htm 00000024 - Disclosure - Operating Lease (Details - Lease Cost) Sheet http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost Operating Lease (Details - Lease Cost) Details http://ctinanotech.com/role/OperatingLeaseTables 24 false false R25.htm 00000025 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments) Sheet http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments Operating Lease (Details - Operating Lease Minimum payments) Details http://ctinanotech.com/role/OperatingLeaseTables 25 false false R26.htm 00000026 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ctinanotech.com/role/RelatedPartyTransactions 26 false false R27.htm 00000027 - Disclosure - Notes Payable (Details Narrative) Notes http://ctinanotech.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://ctinanotech.com/role/NotesPayable 27 false false R28.htm 00000028 - Disclosure - Stockholders' Equity (Details - Warrant activity) Sheet http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity Stockholders' Equity (Details - Warrant activity) Details http://ctinanotech.com/role/StockholdersEquityTables 28 false false R29.htm 00000029 - Disclosure - Stockholders' Equity (Details - Warrants by exercise price) Sheet http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice Stockholders' Equity (Details - Warrants by exercise price) Details http://ctinanotech.com/role/StockholdersEquityTables 29 false false All Reports Book All Reports cavitation_i10q-093023.htm cvat-20230930.xsd cvat-20230930_cal.xml cvat-20230930_def.xml cvat-20230930_lab.xml cvat-20230930_pre.xml cavlogo.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cavitation_i10q-093023.htm": { "nsprefix": "CVAT", "nsuri": "http://ctinanotech.com/20230930", "dts": { "inline": { "local": [ "cavitation_i10q-093023.htm" ] }, "schema": { "local": [ "cvat-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "cvat-20230930_cal.xml" ] }, "definitionLink": { "local": [ "cvat-20230930_def.xml" ] }, "labelLink": { "local": [ "cvat-20230930_lab.xml" ] }, "presentationLink": { "local": [ "cvat-20230930_pre.xml" ] } }, "keyStandard": 133, "keyCustom": 8, "axisStandard": 10, "axisCustom": 0, "memberStandard": 9, "memberCustom": 11, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 58, "entityCount": 1, "segmentCount": 21, "elementCount": 249, "unitCount": 4, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26, "http://fasb.org/us-gaap/2023": 239 }, "report": { "R1": { "role": "http://ctinanotech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R2": { "role": "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R3": { "role": "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R4": { "role": "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R5": { "role": "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R6": { "role": "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R7": { "role": "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R8": { "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R9": { "role": "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroup", "longName": "00000009 - Disclosure - Contracts with Desmet Ballestra Group", "shortName": "Contracts with Desmet Ballestra Group", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "CVAT:ContractWithDesmetBallestraTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "CVAT:ContractWithDesmetBallestraTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R10": { "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestment", "longName": "00000010 - Disclosure - Investment in equity method investment", "shortName": "Investment in equity method investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R11": { "role": "http://ctinanotech.com/role/OperatingLease", "longName": "00000011 - Disclosure - Operating Lease", "shortName": "Operating Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R12": { "role": "http://ctinanotech.com/role/RelatedPartyTransactions", "longName": "00000012 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R13": { "role": "http://ctinanotech.com/role/NotesPayable", "longName": "00000013 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R14": { "role": "http://ctinanotech.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R15": { "role": "http://ctinanotech.com/role/CommitmentsAndContingencies", "longName": "00000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R16": { "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000016 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R17": { "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R18": { "role": "http://ctinanotech.com/role/OperatingLeaseTables", "longName": "00000018 - Disclosure - Operating Lease (Tables)", "shortName": "Operating Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R19": { "role": "http://ctinanotech.com/role/StockholdersEquityTables", "longName": "00000019 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R20": { "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)", "shortName": "Organization and Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_StockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_StockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R21": { "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_OneVendorMember_us-gaap_AccountsPayableMember_us-gaap_ProductConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R22": { "role": "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative", "longName": "00000022 - Disclosure - Contracts with Desmet Ballestra Group (Details Narrative)", "shortName": "Contracts with Desmet Ballestra Group (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2021-10-012021-10-30", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "CVAT:ContractWithDesmetBallestraTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2021-10-012021-10-30", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "CVAT:ContractWithDesmetBallestraTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R23": { "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative", "longName": "00000023 - Disclosure - Investment in equity method investment (Details Narrative)", "shortName": "Investment in equity method investment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:EquityMethodInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_AmeredevMember", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R24": { "role": "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost", "longName": "00000024 - Disclosure - Operating Lease (Details - Lease Cost)", "shortName": "Operating Lease (Details - Lease Cost)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R25": { "role": "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments", "longName": "00000025 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments)", "shortName": "Operating Lease (Details - Operating Lease Minimum payments)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R26": { "role": "http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000026 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R27": { "role": "http://ctinanotech.com/role/NotesPayableDetailsNarrative", "longName": "00000027 - Disclosure - Notes Payable (Details Narrative)", "shortName": "Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } }, "R28": { "role": "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "longName": "00000028 - Disclosure - Stockholders' Equity (Details - Warrant activity)", "shortName": "Stockholders' Equity (Details - Warrant activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-06-30_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "unique": true } }, "R29": { "role": "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice", "longName": "00000029 - Disclosure - Stockholders' Equity (Details - Warrants by exercise price)", "shortName": "Stockholders' Equity (Details - Warrants by exercise price)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "CVAT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "CVAT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cavitation_i10q-093023.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of antidilutive shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r22", "r23" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r54", "r206" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r57", "r77", "r310", "r326", "r327", "r330", "r346", "r413" ] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r288", "r290" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r157", "r409", "r466", "r476", "r477" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r66" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "auth_ref": [ "r159", "r160", "r162" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of changes in:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://ctinanotech.com/role/OperatingLease" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating Lease", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r285" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r440" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net Loss per share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r123", "r124", "r125", "r126", "r127", "r133", "r135", "r136", "r137", "r139", "r274", "r275", "r302", "r316", "r400" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r8" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r440" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r118", "r119", "r120", "r140", "r301", "r329", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r364", "r366", "r367", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r418" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r66", "r113" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r439" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r439" ] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestment" ], "lang": { "en-us": { "role": { "label": "Investment in equity method investment", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r92", "r161", "r164", "r446" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r445" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss from equity method investment", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r3", "r61", "r84", "r145", "r158", "r313" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r36" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r449", "r453" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r157", "r409", "r466", "r476", "r477" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r24", "r27", "r40", "r41", "r157", "r394", "r448" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r52", "r256", "r473" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r159", "r160", "r162" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r434" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r24", "r27", "r40", "r41", "r157", "r394" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r433" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r432" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r10" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note payable, non-current", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r15" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r443" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r28", "r29", "r30", "r87", "r88", "r90", "r91" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r95", "r100", "r116", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r260", "r264", "r276", "r413", "r464", "r465", "r471" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r430" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r431" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r469" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r415", "r416", "r419", "r420", "r421", "r422" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r157", "r447" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r63", "r116", "r141", "r148", "r152", "r154", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r276", "r402", "r464" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "verboseLabel": "Net loss", "negatedLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r62", "r68", "r85", "r94", "r101", "r102", "r105", "r116", "r121", "r123", "r124", "r125", "r126", "r129", "r130", "r134", "r141", "r148", "r152", "r154", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r275", "r276", "r315", "r365", "r384", "r385", "r402", "r423", "r464" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r435" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on forgiveness of note payable", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r3", "r32", "r33" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term - operating leases (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r291", "r412" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable", "label": "Notes Payable [Default Label]", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r9", "r82", "r475" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r65", "r367" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://ctinanotech.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r295", "r296", "r297", "r298", "r299", "r331", "r332", "r333", "r368", "r369", "r370", "r390", "r392" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r81", "r99", "r116", "r141", "r149", "r153", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r260", "r264", "r276", "r306", "r357", "r413", "r425", "r464", "r465", "r471" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued payroll and payroll taxes due to officers", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r241" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r241" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r428" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r155", "r301", "r317", "r318", "r319", "r320", "r321", "r322", "r397", "r408", "r414", "r450", "r462", "r463", "r466", "r476" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r45", "r86", "r106", "r144", "r283", "r371", "r423", "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r6" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "auth_ref": [ "r155", "r301", "r317", "r318", "r319", "r320", "r321", "r322", "r397", "r408", "r414", "r450", "r462", "r463", "r466", "r476" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r64", "r116", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r276", "r464" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, exercisable and vested", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r39" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r16", "r48", "r307", "r344" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r51", "r89" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r38" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r428" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r428" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Operating lease right of use asset, net", "verboseLabel": "Long-term right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r286" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r37" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r417" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r117", "r179", "r180", "r181", "r182", "r183", "r185", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r203", "r284", "r403", "r404", "r405", "r406", "r407", "r454" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "CVAT_RevenueFromCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "RevenueFromCustomersMember", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue From Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued payroll and payroll taxes due to officers", "label": "Accrued payroll", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r24", "r27", "r40", "r41", "r157" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r34", "r35", "r43", "r44", "r46", "r49", "r75", "r76", "r117", "r179", "r180", "r181", "r182", "r183", "r185", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r203", "r284", "r403", "r404", "r405", "r406", "r407", "r454" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning balance", "label": "Number of warrant shares outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r13", "r96", "r116", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r261", "r264", "r265", "r276", "r413", "r464", "r471", "r472" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r289", "r412" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "CVAT_ContractWithDesmetBallestraTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "ContractWithDesmetBallestraTextBlock", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroup" ], "lang": { "en-us": { "role": { "label": "Contracts with Desmet Ballestra Group" } } }, "auth_ref": [] }, "CVAT_DisclosureOperatingLeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "DisclosureOperatingLeaseAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease" } } }, "auth_ref": [] }, "CVAT_DisclosureContractsWithDesmetBallestraGroupAbstract": { "xbrltype": "stringItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "DisclosureContractsWithDesmetBallestraGroupAbstract", "lang": { "en-us": { "role": { "label": "Contracts With Desmet Ballestra Group" } } }, "auth_ref": [] }, "CVAT_IncreaseDecreaseInOperatingLeaseRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease right of use asset" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r428" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' deficit:" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r14", "r180" ] }, "CVAT_RevenueFromJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "RevenueFromJointVentureMember", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue From Joint Venture [Member]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investment", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r146", "r158", "r451", "r459" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r366", "r396", "r399" ] }, "CVAT_TwoVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "TwoVendorsMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Vendors [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://ctinanotech.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r74", "r115", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r272", "r389", "r391", "r393" ] }, "CVAT_OneVendorMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "OneVendorMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Vendor [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r142", "r143", "r147", "r150", "r151", "r155", "r156", "r157", "r222", "r223", "r301" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r440" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life", "verboseLabel": "Weighted average remaining life warrants outstanding", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r78" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r94", "r116", "r159", "r160", "r162", "r163", "r276" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "CVAT_NanoReactorSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "NanoReactorSalesMember", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nano Reactor Sales [Member]" } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "CVAT_DesmetMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "DesmetMember", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Desmet [Member]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r94", "r101", "r102", "r110", "r116", "r121", "r129", "r130", "r141", "r148", "r152", "r154", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r259", "r262", "r263", "r275", "r276", "r303", "r314", "r334", "r365", "r384", "r385", "r402", "r410", "r411", "r424", "r452", "r464" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r15", "r50" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r116", "r159", "r160", "r162", "r163", "r276" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning, shares", "periodEndLabel": "Balance at ending, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ] }, "CVAT_EIDLLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "EIDLLoanMember", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "EIDL Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r53", "r69", "r70", "r79" ] }, "CVAT_AmeredevMember": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "AmeredevMember", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ameredev [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r456", "r457", "r467", "r478", "r481" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "negatedLabel": "Stockholders' deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r55", "r58", "r59", "r71", "r347", "r363", "r387", "r388", "r413", "r425", "r455", "r460", "r468", "r481" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "CVAT_WarrantPrice1Member": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "WarrantPrice1Member", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "$0.03-$0.05 [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r304", "r312", "r413" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "CVAT_WarrantPrice2Member": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "WarrantPrice2Member", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "$0.09 [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r56", "r413", "r479" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r427" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r21" ] }, "CVAT_WarrantPrice3Member": { "xbrltype": "domainItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "WarrantPrice3Member", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "$0.12 [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r80", "r98", "r305", "r425" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://ctinanotech.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r72", "r167", "r168", "r395", "r461" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r253", "r254", "r255", "r335", "r456", "r457", "r458", "r467", "r481" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "verboseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r97", "r398" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://ctinanotech.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r73", "r114", "r178", "r184", "r185", "r186", "r187", "r188", "r189", "r194", "r201", "r202", "r204" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r1", "r42", "r160" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expense:" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Loans", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r19" ] }, "CVAT_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r132", "r137" ] }, "CVAT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Number of warrant shares exercisable", "documentation": "Number of warrant shares exercisable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, warrants outstanding, beginning price", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r218" ] }, "us-gaap_ProceedsFromDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDepositsFromCustomers", "crdr": "debit", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advances received", "documentation": "Cash received from customers for deposits on goods or services during the period; excludes deposits with other institutions and time deposits, which pertain to financial services entities." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r292", "r412" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net Loss per share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r123", "r124", "r125", "r126", "r127", "r131", "r133", "r135", "r136", "r137", "r139", "r274", "r275", "r302", "r316", "r400" ] }, "CVAT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding and exercisable" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "CVAT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r131", "r137" ] }, "CVAT_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, expired" } } }, "auth_ref": [] }, "CVAT_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://ctinanotech.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantsByExercisePrice" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining life warrants exercisable" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r25", "r157" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r118", "r119", "r120", "r140", "r301", "r329", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r364", "r366", "r367", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r418" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest/present value", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, vested and exercisable", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/ContractsWithDesmetBallestraGroupDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advances from distributor", "verboseLabel": "Customer advances", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r220", "r221", "r224" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r55" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r437", "r439", "r440" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Advances from distributor", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r300", "r453" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r438" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "lang": { "en-us": { "role": { "label": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r293" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r66", "r67", "r68" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost", "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "lang": { "en-us": { "role": { "label": "Total operating lease liabilities", "verboseLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r287" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, 1,000,000,000 shares authorized, 284,289,740 shares issued and outstanding as of September 30, 2023 and June 30, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r55", "r309", "r413" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r11", "r116", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r261", "r264", "r265", "r276", "r343", "r401", "r425", "r464", "r471", "r472" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r107", "r116", "r142", "r143", "r147", "r150", "r151", "r155", "r156", "r157", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r276", "r303", "r464" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r293" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r308", "r413" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r55", "r345" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r441" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r47", "r474" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r54", "r206" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r55", "r345", "r363", "r481", "r482" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r141", "r148", "r152", "r154", "r402" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current portion", "verboseLabel": "Short-term operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r287" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://ctinanotech.com/role/StockholdersEquityDetails-WarrantActivity" ], "lang": { "en-us": { "role": { "label": "Warrants vested and exercisable", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r17", "r93", "r103", "r104", "r105", "r118", "r119", "r120", "r122", "r128", "r130", "r140", "r165", "r166", "r219", "r253", "r254", "r255", "r257", "r258", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r294", "r323", "r324", "r325", "r335", "r386" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r93", "r118", "r119", "r120", "r122", "r128", "r130", "r165", "r166", "r253", "r254", "r255", "r257", "r258", "r266", "r268", "r269", "r271", "r273", "r323", "r325", "r335", "r481" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "lang": { "en-us": { "role": { "label": "2024 (remaining 9 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r470" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease liabilities maturities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r470" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r439" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r109", "r111", "r112" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r345" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r54", "r345", "r363", "r481", "r482" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r31" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r60", "r83", "r311", "r413", "r455", "r460", "r468" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r442" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee-related liabilities", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r47", "r474" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, non-current portion", "verboseLabel": "Long-term operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r287" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r439" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://ctinanotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r93", "r103", "r104", "r105", "r118", "r119", "r120", "r122", "r128", "r130", "r140", "r165", "r166", "r219", "r253", "r254", "r255", "r257", "r258", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r294", "r323", "r324", "r325", "r335", "r386" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://ctinanotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r24", "r27", "r40", "r41", "r157", "r394" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r24", "r27", "r40", "r41", "r157", "r328", "r394" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(19)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r446": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 48 0001683168-23-007549-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-007549-xbrl.zip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

Y M@*L0]LIX8;_+J._W]EQI,&<+5X5FU^:+P_?;C$)A7TH*^+CXP=-45L)^0TT1 MP=U%7&_,"0.$L0'UPC%I(N+I@T+1;(5[>/ A^9$;\#K7EV2LC'A9QK_",2CH MJ"=3 @V%%5,/L0?PH+:22H-GD,QR<+3)5)5+Q54MOL#J"WXFA]XB_A5+"GAT MI"$!$;F13!T>D#,WG?N 1^SC_^DFYB-]H$*\UCHS- :\,04^]\)[X00@K05\ M/.9X1>0^I.@">PAA[C=[#QA\>)1,@9\'"-@0<+2G'Q[TV:GEB-<-KIC@1'ZL MGRYPMLJFIN&WZ1$R'A(<&U/W#UDI2"^_=NY;/Z^SD7D7_O,???L-"6C^UAA+ M?*"D.OO?ALK9!^%ORM!:F2\.#UR4!22#J64H&08F+6R4"H:F*B"LY3&'L. > M8\,44RKPAL\/=><8AMG#+>AUS+QDYE$EIU:F#*-3[5/.I@C 4GY+UPJ MG3IECQ@#2<= \R,XO@AB(BX:'CH\H"#;#(*=QUGJ3TV%X&U, "(8,?I3?_M2 M?DI4+H;55B8RZO>??S7J__OHWJ,/,*'QG(PG0QPO8(,?LF$Q70 =:"!0?;_E M,()/9GX ]S,Y%?Z3,S/]+?0.*33X'3TNPD^'K?DR? M>] 56F_$F8'M ^"B[.OU)(-O6&%NK"'FK:OBQ=T#&=UKZHLQV$5JJGJHR0+X M@L!;IN#ZB[=>XL>O!-](OJ0+L:9MSP%L<>;V)H_\@T+K&[7]^V"Q(W^R@V/$ M*=?@\(#X!E)_VD<$;YCXP%A=*"IQ84T=D:?PO#2;V[ 3Z2UO$[Q0F$P>P^PO M$IX;S\LI>)TJ6.;/DDY,$H57!(F7P:"#C"C\,'9"#6S*\YJH](![0AO'G MBHOSJ^2O1/89C5O)&8U$@+-Y.G99X@9VD0A9%"S+O9.@08DXXTW!4,FMAN0Q M![@])M0@Z;J)OQSPLQH#. M"DDO$2GF4%0-$0D2MF"../9!__>HUC@_XN"Z+!G"NLF<*F2.4X7B<3Z3L&C) M M B)BSDZ&HPJ@6Z2AV Y%0'OM,(Z>G=#S7%,/]SB%'3"HG>.,.UDP' M<[Q3SD9AIJ(ULY;;7#/8R^QP]@=O3#OYZ?0_WL.PV2I+NQ:>/W"P;77 MSUQ)XWN2\(6#*= M329TT>2M#>>_VL4$J.CME,[J5;AP66XV.M5&I[WYJT)O*<0;WI,.[5XSGMW. M_0-@PQ"9^MM&CF^:P@*QW\,J"_MY>+$G[+J==M_[D$H7CMG_/@:'[@O_1+DA M-Z56AZN=A@DV)_^9GP-BP0?J:JI 2"I*D,]KC5*C7"O5.6S4-5O7);C"[:DH M,@\Z?ZT4'73I%>C4CR#N!I*!W@$_%CPMI=4^@&R;0\*!/D5-F ^1TQLL\ MV-KM 4)3I9/VQ/.6B2>[ >)Q22"(%8T0-;2V3$:9/1E%1T:Y39(14!$)T@U4 M&5OJ^G^Y"NI#?Z1.2<0Z5 QO08'IYI(=V4=\M$2^Y5:NSTFUZ=?I.)*#?[!V1LD+)/SX@0 M)/Y"MOX&>I95J#ZL:AK<-:\](H-K2?KCEHFTL"?2N(DTLP:1^A:&7L.2 M-#15U@F!WFBJ@$23E.[>4^"[I4!Z/%%;G0(C/7EH=BZKK:5.'>*EO>*>]G;X MK"$9Z5E#'=U#=1 0>^0NX;;EWI[V=MF]249Z,'&KN$JAM'F99L-5GTR2">K< M)@?%?*LC6N6($.J>2M\]E:[CQ$1Z E)!?9YXT;^]TUYN M*=J++J'32\6%HV_5UX'4D^#TA0]_,9EA/9784X@S-WX$T/?O4:2.Y-2.%8^^ MM3& O$%C:%_,Q%V;.];K=F]Y$M<]DSE7JE+[*U4;OE(%"$_M+T]M_?+4%LOZVU<@J("E M9QH<1IG_189-WW&* +/>I:;MI6(TU#K5:RYYNC!OY_# 2=PYC?XJVR9WOESZ M6>N0S>0ZU?)EHUEO7M2J[6.\S>5HEQ:6^#+VCI2;C4JUT:Y6X%)=NUFO54K0 ML/:L5,>D6.7:E]7J=N_9S5,=UAWV=*+832:3WE\N=7G"V%[KX$[C\G]@E@98U46 _P%]RJ#7O4G?$\;RN6F MWRB<5Z:"5@!Q2]OTA6-RPS9CDB,C/$X6V;\A<49[BGI!]8'+9[R_=*'OA:D] ME_N69.G0L"SP!^;(2UL.0QL>4S^YY_G1R4E)UY&AEWI0=$@PNM)9=Y(\K^D& M?_'SRLP=S=^0%>\P+\"G78ZKU&X3.V0>BGS00OT]?RI8B+ZP ^X2-*$9:-E8 MZ8ZM<[>@\>>MP@QOL1+7#HLEDIC)VLT?Z9\/)O/E* 8+QQ/(/N\B M6G<+&O]-3K@V&6XME101_H%!N>U9)1Y38-B>C]YV41XTU.U[I O3VH# MOCO)]QX?;NM7>J[_N,+FSP2VO6&CW'1U UB5K\7@?$D[CK ,6[B&!4D\ GQ MSIH"PE3)?Y8Q1T*:(*ZQ9S?H/].0A!TM(*#F7Y6,[?#G4!L<4)S,I\)=8'&R MA*LTV6V[N[W<\Y^YM;9S\(&MC.LQ6[&V3Z[>E12- SP:8:&\P[QXT_J(IY1)--YHZPOLPOI%Y;# K(LCG$81O M&\AP3"@BH#J7^K7P1[CX]3K8H/UL 4CL(V1!=\PIR-@NW\W#7"Q2Z@W+J%5P MM9;(BEAB.;QS[N(=FHA_C8R!*M:49Z0;Y!1MBFV4P:_,F3%X5%M\A)Z'+Z^P MFP%# A$GV2!M=_,#T+3GD;70M)OLX;9ZV8UZY;Z.>!VU ?-_JV.B,$RQ22_ M]-OS/PG4J/73&]0M-H1X?1A$ND]PBP;*]Q/3=P?TS%PTQL%$Q>P;YJ*5L+46 M+R73L7%3ROISCG<&J]J$98 MPEEFG'"$Y> _%LT5S@5=*]KT5VW&6CP=VV;X\WEZ)E;D"A(1'N_)_9O>A=HO M9M"F@T/6ZE*GV=GXM3MF%$X"D&%6(#OR'B>J9D]&JT0 MC(Y%+_Y&,Y$X2P>.XUO2?W8G\CC[HWA3NI'D?DR.K]\QJ=TVFD"-?R1@D^,) MG@+.H=<17+E8]=QTQGA:WC(*C]-X#E0SVP@A[03>UC([4U$<1"].H*H.1[(Z M1JB%9+@,M)#12F74:FFH>3F6MY.:8/,<82_,%>O*M9 N/&Y5%4V?'%I.P?C83IT;J1JM +0[QV'3N(V#K7)19(N]+72M MPV*1H,N?Q\[<*?-0PQF/?2<9@S+V:-4ATA9PFMP:52L_2DB0[S>BC!9FR9?$ M9^C'I7-]31UR(C1MEWJFH6KO]YPKS+;%PL0AE.$FU=^,/7T6U]XX>7P9GMKC#>=G7.AD(R!']O5S-O MQA4LY*((7.T/%G8GTNPY6%"5^P[2AF[OR3%ZB*@:IM5,_^+J:O1C0Y=PO([W M,8>I[H2)J"TSG ^RXHD5OV5'?!DLK9>0$)\O'IRS:]LP#541IIT$PB]7C]G' M^N"LP<% M?^_ Y1: S!CR]5*[.JD__^E.KA6M-U+X1EW.;"NMT2?=KLV* MQ_?()%?+;OQ+I46(_5CS^D\NM0G1L'=^MNO\%#T1X.%0HE?*H!0#)BJ\L4@1 MJ(!.UKH3Y5;Z@5Y'TNTPIB)4_FE5#ERT!(H;LDA1+4KZ2.;'G\$X#$@W=ERT+KMMWEI@SSO!NN_6%/U)4$R]LF4$82X;C341]BAH.GK MKD)88H(X[?7?>G=B9B^,7^WOSVFT2B&TN4Z[!,6FL0E] D=V_G:U#2)^$<-X MS/W'*9H,"RIZ_ CO@FYXK:F1"L,B6=L-TMH#7L-KK'4%J[)N=Y*_>_D].%?O MU>\/1YPA&0#>S+0C7N.>2>&A;], )-< ( < W.LOK=[HZ>?H40@'P(+J"6% MB,!RKS7.O;;B#1E9CQ? )4S98 3IXE$TL>>G?F":3?RC[,%Q]PT#:0":8!. M63*-@:I)$R1.$=_U7>:Y\D?O//T>!.^]3L;@>'N062(,YH)@ CQ756DN]^O MR8':ZB\'P!)[/ U"Y,2W"N&%!6IE@K. HO=# SRH^10W@_=9RDLLV/B:KIMT MTT7537B_+U^K#[_%V]'UX\)]E\@8LT07K$OHW$W3T ULIF.A/@M >G3_2T7B MWO% M '@QL#294QR$YCLP_H',7U1-U)$2!^.Y,+-+8,U'U(PLV U$K0^6HH:13>"Z!GUDUNT'\++[N"X$G59GVDT:CQ,CE*OU1E5^% MVEWG*M:Z1"&\)@IMH,N4]U]8H+OB:.V1*-JJRCO)' -\)I0 V0DW9+N&];0Y&DTBAH[M5.1[ MYW4K-_0WC*OEDB3BQ56(RF_8ZH>!>?F&E\2:4N9'DL'+3L8E\4C&Q;M7I3!L MMLQX[PB'=4P;EZ6J6>3'39B*%9 MSUF0=8C^EG/B/LPGTL7;&9'*Q##]>W0R0[CYXVPZTBS&F9:%^\U:7F<';E:J M$*X0RG*;Y2]U,G-3;EC^,XLL&E38N+.@L[W"G]]#[5RKK9(%'>E-:W?JL^Z7 MI?..:79VYZ*VP0.H-7F5_D\*W+.F4 M>'&)E8*.C*>?PY^3C3<4"UTSVG6]@CCD*\F<-UW$>-'VQAP'V)>=WMB.11.- MV$QIZD\&W&3%G^'_OHZL0:%",2W'PG6D(>;9!GKA6NJ05X[I%\=<&VE2_PLW MY+5["<\!CR;\FW=;$X^^O?5)V@A![4]U..(5Z&?)*7 =&"H1&@,$U"!".5!R MMX'H/3"##P_ZDL(K@D0L+?S-D#9\C0A0\M_D:592IOS)!'R'2;QGHZ;W;3]K M/+-ZYON?DQ/N7$*R^)F[X>^QX&FC)Q,I OK,I;F3$TL"BM)S6..)@G-BJ*// M7 Z8FWUAO9 #&?N5<#(F55EF(H$(%?A;'_&"];=W2FP#R/Q(QZ!9GYP.L(G$ M/U\X4JI= -W8MO'[A.N,1 M!K"D87DM?.$:6(I3W#=40'C:_=(GZRWX)6CV@.:WTQ+4DIY?/^'-]-M7#?&/ M)SV$50$&:$2((=Q>VC3KHD2WC//,Z%X=K)H2V18H?]WY(I?B1U'"%K-NP<@L MEW[6.J5.K=G@.M7R9:-9;U[4JNUCKM8HGT:*Z4 0G"/HIW0W ???V.E;N=FH M5!OM:H7#G]K->JU2ZE2A)0'^Y[K:Z+2YYCG7O*FV"/SMPX,/MPIOBA+6@!^Y MS(C"TJS<8HK-JRSD!A-X)^$-J V!,$7 XF6SY@^E$M9M,IKN3--\?-IOW MYI\,W- TAWCB,7D$"SW+A.!.N"7WA'-MR='RJP^G,H["W0]H0D& M RCTWZ.4@\E,\;Q+NP'PI:^+4.A.'OFVY$C;=%.#I M1A+@K]G+S1T%ONK/%.>J1@SDSD##!O0U?FF@);V&AJ3=,+>'Q%1(?'TQ;"2XI?=X&E/'N M4^AUQJ!C8U:B*P;'F>V3*V#3IX6>D6*BZ1VSS*-_ LAD^K'Y$4\[/[20\B1! MD*EU=CX@)EA2*-@AM@74[>J: =?=5-$4C*:&+;MG24"E5TGO=@52T-8>Z5Q3 MAU:-6_V:*)[N1/C>2K?2-_7!G7/EE ;X-?K6T?1B ESI1:?*=#'>""M 1".L M^9-$THF.,\B[P8"'NIT2%(@->T]E[O;-C79$3A@%/\(0;+O4-DS7I0=":ULC MA)1-"*G5"&&U@Y1P28*AJ2'2DBI+Y038\HH66G]0)>Q5XB\,4YL189L_6':H M^2QN,7<%*_])%VY)NKMAH:5\%U-7^L," H^\*MC:TF]V/1L1@&^LJ)M#8-F8 MQ*4/7861F)LEJ#!2=!%!K72^&5NEP# 9HVR36;6\]5 M-YI]1DE=J=$5)2R =": >OF:) M7,B/5,P%)!*^4[LIMHS/Q1L4F9C-QI&&N[CJ_H6FZCHV'_MP):5#K ^#,C]8 M(4)FTIWHQM.U6$GMM2G06 M5G(CO;2BU-\[;//L%C2++; +I""-EZ'AMSB4%.@MR$,YJBKMY$[D\/?Z8W=R MCMJUT!:M[M\1'[/ HRM)D&78=>W?(%]%>1% MZ$O&UTLH[XFFZ(C7A %>904;;[(Z@OPDBZ-8B(4PE?Z2']]5;HJERM9NJK"X M-X68<)WHP#S#V[59_4>*.OMOMD]@J M=7"3P$<"\0&!$N(C*=<_;_L7%0$]KE+,?DT?B<9L5;LEV?L7&3.;$KO.C]8] M?^]R(MS^;-RLV#M0[\6!2OA)Z)HBJ$-4QUZ[):-!-H.I]XK.NI,;<]A1J_I- MM5"(U7\" &C^ A/)JA*[P[0@CNF#HN@E9E!!C)"B,S"(N?-86T..!> LNZJ' MZ1/WW4NMG9%:YRZIU5 5U4M?3%R+]&QD 5:\HSTFFG.2OZ0%12L7S]P\P_M^]X/M[S55K^@M;SFJ>Q$ &: M&Q*H.[LQJU"(W8&#DVV1\P(]MCKZHM=LR4)TFLV__6\-\N_QJJQH'\EI M()XZ83F1OVIA2JU&"HFK((ZUJT) MERWEYTO0I3 6A[6R9".W)7&Y$8B7[/,6B18(E[?U%ODYOQ8_SS.&UN'GQ)K\ MO#9<&^/GM>RD+7!SM/"F\KGC7+%P7$@OW3\X$E[V*S[_EJO";V22'2P]'_G* M(RW7'#UL/7O,<-7>,_MJ[UNH]I[95WM?@\(W4ZG;AX_^HJ+JN>6*JIU\JUCKNN]]>>QGW"RWD'M=!+W60RTYW\ MTLO7K3%ZJ;52:]="9ZCDIC#Y?_Q(U;_XH?.=EDD/&R5:>F [&^'LO.OJE,BV MB2;#E;$-HRI@B9#":7X=[JTB?+6S9K'UY[)>>>IMI'C[67YIJ -:ZEHKX.]3 MX\:PH%6_2YM906;I%4RW\+1 -]+Y.V$\^"G'6M37@3S=G?RYRXZ2F?)S[;FP MZIRKE#\.L$ZB*>B=+(0N[!>R-O1L&7V_MO=S*DAOJOQWK'B-O+X^E3\<$4!1 M8&R5Y,45RL#[VASQ]5BQQ9UE0'#Q379#^\Q;,RV+ULA)+O+:_*YNR3M <2N. MM7NB(?)]HI&S:+=H1Y=:&JJF$J;XU]M?*C/5_HJU5D)W]7[[:R45&J*V>6P[ M-5WT/;R\S$/4BS>X*U-!ME48 M$ );JP'!%&TX9;7=M_5F3XPP3GQ+MX=T7^;ZC:7>.9]'/R[.[YTV%2Z4]! V M/A1RY$2/H6::%216:5:PX"S'VR#8@K\[ WZ,Y[0!F[^MAA61('VIMLQK8WVV M&D8AXGX0[Q#9Q3_N$L/>XU'U"V/M<:\P)83G?V^\+$\(:OQ532%SE MSL\'6TL(2VTT(2P1)B%L&H^1A&F?4K5[02S?%<_0SB6$I>)-")M[V?]-YLE$ M$A*("NNSL;A\N!#.WXSLV(*@B7"MJ=X([J,)?DTC/[:C[N-4YKTDA$6)^#5* MMX?LEQF:G)?*!IM2*%>#W&6$+=VXWM\8_9I!8(690Q7[L[[,'N>?_(-,^Q<-MBTR(LZ]) ZQC@^+F0R^[246-R+ MF++!\+[M4XDVLF?Q!$*RQX5DQ&DJ[V(+(XNG;.;JP'$ZY$6POR8;+,K]6Y6[ MBKD8$RW?6QK8OO)N+)5W=R>Q[PU/$J:$;W9?PG<+)7RS^Q*^.\Q-&ZP3O'NU M>_-+UNXMM2^Y\WKSKGUXX*[2&R7HY+_)TZRDL$5(H)%@)$E9,1';*<*;ZB:3 MJ>XD^6.H-BN)826?7K\(KXV3OZ#2KAWQ*V:[/G<0)\W<)%]]297/\RM7/%T. MC$S7)_8UR9YE\M=B.:E<)7>Q\&KXU.^(,N:7@VBEM8='\XYGUX6Y$?PNT@C# MQ+HW=',B]-(7&$6;&M@_\2 7V+%\R)_1T-2OOQ=C39+,%7R3 M)X*R$&+-20DP9M]TS_$=2OF)"[U;.X]-@?#XZ[:%_)?-&T$+>K:8,)TE01LTHX664G(RT05MLB MZSA0&+W$3Q9"2?Q5N+'BXD8LTC7$ZZB"Z+]8B!L#I#F2'"/"T$N*6)?XGB03 M,8@U@4>L]ZH]4?_Y^[Q>6^7Z2GBQ7NWWD6 QPD#7KE'.A;4>Y&\(A'DYA)! M21#@KI^.M3^2GD&P^4AE11M7+NY:^58NIFM+X:2R!2OH>0;L=D5(&'3N!?%" M.WME-*XAC*=D<+C[.TN:VN==)&#S5!WZ2E]+\-;A[Q8@2NUCHY3*86!"QR,> M_FD\7OQ1?V5>HS2GPS&=#2?^&P-*MQ1$,X:5XP'8[?!@^6>IXT,Y\]$:O8\< M@RY_NYC5/I7'QO8VS=_\GOA&YD[@G' M*R*D, #L''H=0;Z"OJO:+O%LC&@-#+>C0*?_JR;G,NZU>%( M5L<(M1"II3+-L&+"X=E!YMHXR_^6"L-54NK7TZ=L.X!/-566"9]:GPW^%?LZ MHHD@;*7V^Y* M)UCVF \Q\VJ(:^:OA5671*1"Q@TP&.(PU'PY\[B7.XLXP7! M;'>2,2@3HQAIUHK'7HUZ=V$4)R]/>BV_BK4;G485G^$2A\[U,?XY4=(-3>J9 MAJKM&AW-16W"_ID1 M;!L7O9A)AXL:KK!U_@*HZLW!"IG@ 4*HTQT:5 "!2= )?X4R"U#+2I[%\NL?[I?/PVQM[:#RUV@WC=RN@%B>?K;-S,62FK=8O)'RE MC"BMF!T^I=\M:!8GC@ 5PO_@>NTS+R-R+ O!$,% (OQ04D3O%ZXG;Y FJ>*T MMJV^"K()5((_D 2/%F\@FO1!M0SI24ET#=$QQD3\)5S>#G\,,K'FG8#JD!BL MW >10?L1?T0;2&MMC1L-(.;,LZ"L#>E/54 MP5[J[RHT_E(_%974)[6N?[2$QWSAS'A)/VR^E&0Y2%P?.X6?(8EE1'CM+9N1 M,0JB:#I>KY0A\]=X 9O>OC4+U&8RD;9/72R3SJ.32=7NQ)3*'>7L.5GZODIY MVQ!1T\7BB97;F2.@$/XVM&AZT]5[8I%.:P4I,OL:6MO?Q#43D-*YB!LJKG21 M-XQ1L\,6XFY!XZ\;\NZ:G^9H)).:%+P,-'8NJR\UA1(0WGS/-99'I/.IU^JK MU%XEG!!""]""//#Y,P>U_:#@S>P"W2!#?HD@J[JI(7+3C&B%/EX#)SF+V%^! MB8!0:G"Q'XLC*+[80(:5&SA!MU>7C]IM4_N^Z9S ^38".4G%)( )@0+^KI7) MU.[$GOR[U_8Q;- F,Q775N*!MR75(>I /NZTH,C]Z=^D$E?7-7&+5Y1#RPQ8 M!LTK?N=D.;U?D29=;) V_^X->CNBXYU4:]W()/MRJN]SDC#E5'/[: MVY=3W6%NBKU(]D[642W8=50;S4ZUS76:0<5#SVN-4J-<*]5=942AF&JC=%NI MX0<^?NUIW"<,/:WI.*0U'=%L34?H59,F879:R"_V54\1"K5 &N80#R"$-DB1 M+O C"'5H)CJ:LJ.:VCVO2!,2#RK;ZA(B7(IX@QTSB";!G\W^N:4^[6JM>L4. M,N&GVQAPJ8^%F6*P2Z-87M[@\00)Z1T,YYFL"H^$,2T?J9 HN7RD38/2G;1& MA7.^.+EN/_$KU(Z=K6C<@'I.2>Z$)4_^N9>*B&G M-JV'"Z$Z%_"< SUG@6^W:HN0]@CP%JG%1M-06DWJC\&G?);H5G(=) P4[,G> M2S &-NI/N0\:ZB--PZR'[;D!TI"D'!\>F(I,BF9!&O6+I"/LBHH81]BP.^9X MG0,;/97X N9?F9J%Q^2KY!?KIW)'FO[J!4U_8^KV-[ K[%O5U-BW'P\/))WC M\?*?>9''#*B-5(VN1,4*#I.E+(^)ETQ_P(O OCJ6'0 8,!YW)JE<54':_9@M M%\/%#? *1/2,9'4$ZQGA%Q6Z,CC04X>8W8':L0DA0A;R2).0@:GE\,"PT#?& M,_ &QOZ8ZR&.)2=SLO1D2N05 2./Y"B/1C*@#4.LG\:]S_Y$%;T,.^-U26_V MIUA]3/\;('DR[C)&X0;H3DJ]W"]4U!^:KKHIJ[.ZD4M9OKG)".WLG0F,U##U(#K>0M,4$^R'Y M.W6<[=,='CA.'>:G9X3Y "F8]-&(UR@WP'B:2!JIO4C&@+M'F \)P^)?0,N3 M A>6O,5,A@<>8:G#?6!RX*)4NK$$ 0@=S%=#4[XG@.#Q@<=O%8GXFD0QD4TI M$3KG[4%N3]NGSB"8OPDLDJ)CRB9Q!>+'GJO:$"/SY E&CILV0QG2&R$O,.L6P^P' ,*NMIK'$, M#W0E\$^P3U0X2:1AE)8]*=<^^>62;NX13HGBTL"!DK&)*ELBI@49!DFAWE%>14%B)A%& ?U(0"%E0XA_( MM[K!&(F.FIA$A[ R %0I R7-]7M* 6FT&/N6<"ZKX:U/&L\&C *T1 MSDS5$$,BT9027@?#H36>2V<<'L#M.H%L")NE+T'B)C=&O,;:#G)7IH*L"3*G MW&_5Y/2!:LI C+Q(-QK3!"O(OY!IW3L..=&J\F JA D.#PA; !C68+YO 040 MW4H#0& N8#ZQMXMQ)3,)_@O/*R;9"ZR>#:C(:3':=WO9UGKQZ[#:D[Z8CU7]\?GX3O+ZDM:O5J=W)UW4ZGG\Y%O,='WPC('(/Y'6KS^>+@\,!' MAX/$Y^Y5-@#@!7,7%K183@\D84!I"XM[GLD"$$JRY65AMB/5Y1R9@?\P:+X$ M_"@[Y5)LLULR&#",PY@DQS:"IA-AVC.Q58VE/E9XH'_Z,I6@S-@(O]QC3C2) M:E@DW1UI=.R6;" +3.(S\4ZI:@S??[Q45IR^JNDJER\UV"T942*];6?:C/P1 MA6KF9OBCKZ@X7*CYB"4H+&?;.#T]W6_^'_\2-7M.2/J5QA9)8CC M9#XHHY%ADMFBT]8(T9%@!?;Q"ZJ&*9['%'Y/'7K\E\:#4Z^;/6@V; !WP-$@ M5I@]U33^PT$W"VB$2(=C\"H MQI8;,>A&9@]K"K=/T)>TX3%PMT2*QEHVA!]T'A5_',#T9-&B>]6'!U$M>WF9 M.V5T'QZ 8'$;N[:Y2.U':J< -R@64,R^M*32 A@W;)C$-$LI@.*] AJ,/$C" MLW4))G]3\99:,LJ\IL&V_N1E$W6EFEO$M#J7CYEM0&8ND>8"A6( M$2HJV$.F1FN2D> "M)G!9P0.D:*:MX/:$XI?E''G$#Z&U!_E40P M!AIYI()]8F *I@/>!\.[<0/2$-,TQJ4!IB>)TE!59ND<(M,1B'1%_(3],D2T MM"6 *3'T3;BBX:"/6*BJ57#"-13WHFJ/A+IIDV^R47A/,=FY]Y/NI6YBF]B9 MYT62,2AXY_EG7I+)03>CH[YIF'@0#)S:HWVHX1?=A(*1$K -E56Z*\2!H1N" M/^NGH12$1$)MO.=W @!0'DR-"1O#*PR L&"=?8D>O;N08/FP04/8, #ELR4( MK-@:^/@JUM[W+-+-M6F4PF%;"+C(>(C# [KF*6QYA3?L,K:O#7@%9G.@W#1) M8P&)R,5=Y/9U4^E4=S))BPFUIW\WFFL?9BV$A4AJ"Y"Y@)UU)XV\,$S<3XK- MRN,. 8;];6/<*-7%LCKY$1-> N/L>*8[N6D*J7;J.MTO.UWLMI@<$Y[1L$&::;7^O&;1CR

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